Document:

exv10w31

 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Exhibit 10.31

U.S. CO-PROMOTION AGREEMENT

BAYER PHARMACEUTICALS CORPORATION

and

ONYX PHARMACEUTICALS, INC.

March 6, 2006

 

 

Table of Contents

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Page	 
	 
	ARTICLE I	 	DEFINITIONS	 	 	1	 
	ARTICLE II	 	GRANTS OF RIGHTS	 	 	11	 
	 
	 	Section 2.1	 	 	 	Co-Promotion Rights Relating to the Co-Promotion Collaboration Product	 	 	11	 
	 
	 	Section 2.2	 	 	 	Co-Promotion Rights of other Collaboration Products, if any	 	 	11	 
	ARTICLE III	 	MANAGEMENT	 	 	11	 
	 
	 	Section 3.1	 	 	 	Overview	 	 	11	 
	 
	 	Section 3.2	 	 	 	Joint Marketing Committee	 	 	12	 
	 
	 	Section 3.3	 	 	 	Committee Decision Making	 	 	13	 
	 
	 	Section 3.4	 	 	 	Obligations of the Parties	 	 	13	 
	ARTICLE IV	 	RESPONSIBILITIES OF ONYX	 	 	14	 
	 
	 	Section 4.1	 	 	 	Promotion of the Co-Promotion Collaboration Product by Onyx	 	 	14	 
	 
	 	Section 4.2	 	 	 	CRM System and Sales/Prescriber Data	 	 	15	 
	 
	 	Section 4.3	 	 	 	Onyx Sales Force	 	 	15	 
	ARTICLE V	 	RESPONSIBILITIES OF BAYER	 	 	16	 
	 
	 	Section 5.1	 	 	 	Promotion of the Co-Promotion Collaboration Product by Bayer	 	 	16	 
	 
	 	Section 5.2	 	 	 	CRM System and Sales/Prescriber Data	 	 	17	 
	 
	 	Section 5.3	 	 	 	Bayer Sales Force	 	 	18	 
	 
	 	Section 5.4	 	 	 	Manufacture, Shipment, Booking, Invoicing, etc. of the Co-Promotion Collaboration Product	 	 	18	 
	ARTICLE VI	 	EMPLOYEES; TRAINING AND MARKETING MATERIALS	 	 	19	 
	 
	 	Section 6.1	 	 	 	Compensation of Sales Representatives	 	 	19	 
	 
	 	Section 6.2	 	 	 	Marketing Materials	 	 	20	 
	 
	 	Section 6.3	 	 	 	[ * ] of Employees	 	 	21	 
	 
	 	Section 6.4	 	 	 	Promotion of [ * ]	 	 	21	 
	ARTICLE VII	 	REGULATORY MATTERS	 	 	21	 
	 
	 	Section 7.1	 	 	 	Licenses	 	 	21	 
	 
	 	Section 7.2	 	 	 	Labeling and Marketing Materials	 	 	21	 
	 
	 	Section 7.3	 	 	 	Efficacy and Safety Information	 	 	21	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

-i-

 

Table of Contents
(CONTINUED)

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Page	 
	 
	 
	 	Section 7.4	 	 	 	Recalls	 	 	22	 
	 
	 	Section 7.5	 	 	 	Pharmacovigilance Agreement	 	 	23	 
	 
	 	Section 7.6	 	 	 	Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use	 	 	23	 
	ARTICLE VIII	 	ECONOMICS OF CO-PROMOTION; PROFIT SHARING	 	 	23	 
	 
	 	Section 8.1	 	 	 	Overview	 	 	23	 
	 
	 	Section 8.2	 	 	 	Joint Profit and Loss Statement	 	 	23	 
	 
	 	Section 8.3	 	 	 	Reporting Sales	 	 	24	 
	 
	 	Section 8.4	 	 	 	Allowable Expenses	 	 	24	 
	 
	 	Section 8.5	 	 	 	Determination of Marketing Profit and Loss	 	 	25	 
	 
	 	Section 8.6	 	 	 	Allocation of Marketing Profit and Loss and Related Payments	 	 	25	 
	 
	 	Section 8.7	 	 	 	[ * ]	 	 	26	 
	 
	 	Section 8.8	 	 	 	Reimbursement of Development Payments	 	 	26	 
	 
	 	Section 8.9	 	 	 	Budget	 	 	26	 
	 
	 	Section 8.10	 	 	 	Royalties	 	 	26	 
	 
	 	Section 8.11	 	 	 	Federal and State Tax Characterization	 	 	26	 
	ARTICLE IX	 	RECORDKEEPING AND AUDITS	 	 	26	 
	 
	 	Section 9.1	 	 	 	Audits	 	 	26	 
	 
	 	Section 9.2	 	 	 	Maintenance of Books and Records	 	 	27	 
	 
	 	Section 9.3	 	 	 	Compliance Audits	 	 	27	 
	ARTICLE X	 	TERM AND TERMINATION	 	 	27	 
	 
	 	Section 10.1	 	 	 	Term of Agreement	 	 	27	 
	 
	 	Section 10.2	 	 	 	Breaches (General)	 	 	27	 
	 
	 	Section 10.3	 	 	 	Allegations of Material Breach	 	 	28	 
	 
	 	Section 10.4	 	 	 	Termination of Collaboration Agreement	 	 	29	 
	 
	 	Section 10.5	 	 	 	Effects of Termination	 	 	29	 
	 
	 	Section 10.6	 	 	 	Survival	 	 	29	 
	ARTICLE XI	 	CONFIDENTIALITY	 	 	30	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

-ii-

 

Table of Contents
(CONTINUED)

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Page	 
	 
	ARTICLE XII	 	INDEMNIFICATION AND INSURANCE; LIMITATION OF LIABILITY	 	 	30	 
	 
	 	Section 12.1	 	 	 	Indemnification by Onyx	 	 	30	 
	 
	 	Section 12.2	 	 	 	Indemnification by Bayer	 	 	31	 
	 
	 	Section 12.3	 	 	 	Product Liability Claims	 	 	32	 
	 
	 	Section 12.4	 	 	 	Direct Claims	 	 	34	 
	 
	 	Section 12.5	 	 	 	Insurance	 	 	35	 
	 
	 	Section 12.6	 	 	 	Limitation of Liability	 	 	35	 
	 
	 	Section 12.7	 	 	 	Disclaimer of Warranties	 	 	35	 
	 
	 	Section 12.8	 	 	 	Regulatory Compliance	 	 	36	 
	ARTICLE XIII	 	REPRESENTATIONS, WARRANTIES AND COVENANTS	 	 	37	 
	 
	 	Section 13.1	 	 	 	Representations by Onyx	 	 	37	 
	 
	 	Section 13.2	 	 	 	Representations by Bayer	 	 	38	 
	ARTICLE XIV	 	NOTICES	 	 	39	 
	ARTICLE XV	 	DISPUTE RESOLUTION	 	 	40	 
	ARTICLE XVI	 	MISCELLANEOUS PROVISIONS	 	 	40	 
	 
	 	Section 16.1	 	 	 	Assignment	 	 	40	 
	 
	 	Section 16.2	 	 	 	Governing Law	 	 	40	 
	 
	 	Section 16.3	 	 	 	Waiver	 	 	40	 
	 
	 	Section 16.4	 	 	 	Entire Agreement	 	 	41	 
	 
	 	Section 16.5	 	 	 	Severability	 	 	41	 
	 
	 	Section 16.6	 	 	 	Relationship of the Parties	 	 	41	 
	 
	 	Section 16.7	 	 	 	No Implied Licenses	 	 	41	 
	 
	 	Section 16.8	 	 	 	Public Announcements	 	 	42	 
	 
	 	Section 16.9	 	 	 	Counterparts	 	 	42	 
	 
	 	Section 16.10	 	 	 	Force Majeure	 	 	42	 
	 
	 	Section 16.11	 	 	 	Interpretation	 	 	43	 
	 
	 	Section 16.12	 	 	 	Certain Expenses and Commissions	 	 	43	 
	 
	 	Section 16.13	 	 	 	Headings	 	 	43	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

-iii-

 

Table of Contents
(CONTINUED)

	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	Page	 
	 
	 
	 	Section 16.14	 	 	 	Days	 	 	43	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

-iv-

 

U.S. CO-PROMOTION AGREEMENT

     This U.S. CO-PROMOTION AGREEMENT (this “Agreement”) is entered into as of this 6th day of
March, 2006 between BAYER PHARMACEUTICALS CORPORATION, a Delaware corporation (“Bayer”) and ONYX
PHARMACEUTICALS, INC., a Delaware corporation (“Onyx”).

RECITALS

     WHEREAS, Bayer’s predecessor, Miles Inc., and Onyx entered into a Collaboration Agreement
dated April 22, 1994, as amended on April 24, 1996, February 1, 1999 and as further amended by this
Agreement (as amended, the “Collaboration Agreement”), pursuant to which the parties agreed to
conduct a collaborative research program intended to discover and develop Ras Function (as defined
by the Collaboration Agreement) modulators for all human and animal therapeutic, prophylactic, and
diagnostic indications;

     WHEREAS, in connection with the Collaboration Agreement, Bayer and Onyx have developed BAY
43-9006 (sorafenib), now known as Nexavar, a pharmaceutical compound which is a Co-Promotion
Collaboration Product under the Collaboration Agreement;

     WHEREAS, on December 20, 2005 (the “Co-Promotion Effective Date”), the parties obtained United
States Regulatory Approvals to market and sell the Co-Promotion Collaboration Product;

     WHEREAS, under Section 13.4 of the Collaboration Agreement, Onyx has exercised its option to
Co-Promote the Co-Promotion Collaboration Product in the United States; and

     WHEREAS, Bayer and Onyx desire to Co-Promote the Co-Promotion Collaboration Product in the
United States, upon the terms and conditions set forth herein.

     NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth in this
Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is
hereby acknowledged, the parties hereto agree as follows, with the intent to be legally bound:

AGREEMENT

ARTICLE I

DEFINITIONS

     Capitalized terms used herein without definition shall have the meanings specified in this
Article I (such definitions to be equally applicable to both the singular and plural forms of the
terms defined). Unless otherwise specified, all references in this Agreement to “Sections” are to
Sections of this Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

1

 

     “ACCME Standards” shall mean the standards set forth by the Accreditation Council for
Continuing Medical Education relating to educating the medical community in the United States.

     “Act” shall mean the United States Federal Food, Drug and Cosmetic Act, as it may be amended
from time to time.

     “Advertising and Education” shall have the meaning specified in the Collaboration Agreement.

     “Affiliate” shall have the meaning set forth in the Collaboration Agreement.

     “Agreement” shall have the meaning set forth in the Preamble and shall include all appendices,
exhibits and schedules referenced herein or attached hereto, and as the same may be amended or
supplemented from time to time hereafter pursuant to the provisions hereof.

     “Allowable Co-Promotion Expenses” shall mean those expenses incurred by the parties following
the date of receipt of United States Regulatory Approval that consist of (i) [ * ], (ii) [ * ],
(iii) [ * ], (iv) [ * ], (v) [ * ], (vi) [ * ], (vii) [ * ], (viii) [ * ]; (ix) [ * ], (x) [ * ],
(xi) [ * ], (xii) [ * ], (xiii) [ * ]; and (xiv) [ * ].

     “Allocable Co-Promotion Overhead Costs” shall mean all general and administrative overhead
costs of the functions that directly support the promotion of the Co-Promotion Collaboration
Product under this Agreement, including without limitation costs reasonably attributable to
compliance, account administration, accounts payable and receivables management, interest on
working capital associated with inventory and receivables of Co-Promotion Collaboration Product,
and out-of-pocket, Third Party costs incurred for legal and accounting functions. Unless otherwise
agreed to by the Executive Committee, all general and administrative corporate overhead items that
are included in this definition of Allocable Co-Promotion Overhead Costs shall be [ * ] for Bayer
at [ * ] at the Co-Promotion Effective Date and shall remain at such level pending adjustment in
accordance with this definition by the Executive Committee. Unless otherwise agreed to by the
Executive Committee, Allocable Co-Promotion Overhead Costs for Onyx shall be [ * ].

     “Allowable Expense Report” shall have the meaning set forth in Section 8.4(a).

     “Annual Sales Targets” shall mean the aggregate level of Gross Sales each party’s sales force
is required to achieve as set forth from time to time in the Budget.

     “Applicable Laws” shall mean all applicable federal, state and local laws, regulations, rules
or guidelines that govern the Co-Promotion Program and activities and services in the United States
and the other transactions contemplated by this Agreement (including without limitation the Act, as
the same may be amended from time to time).

     “Asserting Party” shall have the meaning set forth in Section 12.4(a).

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

2

 

     “Bayer” shall have the meaning set forth in the Preamble.

     “Bayer Indemnified Party” shall have the meaning set forth in Section 12.1(a).

     “Bayer Marketing Services” shall have the meaning set forth in Section 5.4(d).

     “Breaching Party” shall have the meaning set forth in Section 10.2(a).

     “Budget” shall mean the annual budget for Allowable Co-Promotion Expenses to be incurred by
both parties during each Contract Year of the Term in connection with the promotion and marketing
of the Co-Promotion Collaboration Product, as annually prepared by the JMC and approved by the
Executive Committee (or any duly constituted sub-committee thereof charged with such authority by
the Executive Committee).

     “Call Plan” shall mean the call plan for detailing and implementing the sale of Co-Promotion
Collaboration Product in the relevant territories by the Sales FTEs, which call plan shall be
agreed upon by the JMC not later than [ * ] days prior to the introduction of additional products
and the commencement of detailing of such additional products by either party’s Sales FTEs into the
marketplace, and which call plan may be amended from time to time by the JMC.

     “CIA” shall mean the Corporate Integrity Agreement between the Office of Inspector General of
the Department of Health and Human Services and Bayer Corporation dated January 23, 2001.

     “Claims” shall mean any and all claims, suits, proceedings or causes of action brought against
a party.

     “Code of Conduct” shall mean the Healthcare Fraud and Abuse Code of Conduct of Bayer.

     “Collaboration Agreement” shall have the meaning set forth in the Recitals.

     “Collaboration Revenue” shall mean Co-Promotion Net Sales plus US Sublicense Revenues.

     “Commercially Reasonable Efforts” shall mean the level of efforts and resources (including the
promptness with which such efforts and resources would be applied) commonly used [ * ] with respect
to a product of commercial potential [ * ] to the Co-Promotion Collaboration Product at a [ * ],
taking into consideration its [ * ] and all other relevant factors.

     “Committee” shall mean any of the Executive Committee or JMC, or any other committee operating
under delegated authority and formed with the approval of the Executive Committee or JMC.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

3

 

     “[ * ] Product” shall mean any product having the [ * ] as the Co-Promotion Collaboration
Product and that is intended as a [ * ] for, and [ * ] for, the Co-Promotion Collaboration Product.

     “Confidential Information” shall have the meaning set forth in the Collaboration Agreement, as
amended to include any Information (as such term is defined in the Collaboration Agreement)
furnished by one party to another pursuant to this Agreement.

     “Contract Year” shall mean a 12-month period commencing as of January 1 and ending as of
December 31. For the purposes of this Agreement, the first Contract Year shall commence on the
Co-Promotion Effective Date and end on December 31 of the same calendar year; provided, however,
that for purposes of measuring [ * ] under Sections 4.1 and 5.1 hereof, the first Contract Year
shall commence on and as of January 1, 2006.

     “Controlling Party” shall have the meaning set forth in Section 12.3(e).

     “Co-Promote” or “Co-Promotion” shall mean the joint promotion of the Co-Promotion
Collaboration Product through Bayer, Onyx and their respective sales forces under a single
trademark in the United States.

     “Co-Promotion Advertising and Education Expenses” shall mean the costs (excluding Allocable
Co-Promotion Overhead Costs or any other overhead costs) incurred by a party or for its account
which are specifically identifiable to the Advertising and Education of the Co-Promotion
Collaboration Product in the United States consistent with the Co-Promotion Program.

     “Co-Promotion [ * ]” shall mean the [ * ], as determined in accordance with GAAP on a basis
consistent with Bayer’s annual audited financial statements.

     “Co-Promotion Collaboration Product” shall mean any pharmaceutical form or dosage of the
experimental compound designated as Bay 43-9006 (sorafenib).

     “Co-Promotion Distribution Costs” shall mean the costs incurred by Bayer or for its account in
connection with the freight, transportation, insurance, handling, packaging and distribution of the
Co-Promotion Collaboration Product in the United States, which shall be [ * ] of the Co-Promotion
Collaboration Product.

     “Co-Promotion Effective Date” shall mean the date specified in the Recitals above.

     “Co-Promotion Marketing Expenses” shall mean the costs and expenses (not otherwise included in
Co-Promotion Advertising and Education Expenses or as Co-Promotion Selling and Promotion Expenses,
and excluding Allocable Co-Promotion Overhead Costs or any other overhead costs) incurred by the
parties in connection with the marketing and support of the Co-Promotion Collaboration Product and
approved by the Executive Committee, including without limitation [ * ].

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

4

 

     “Co-Promotion Marketing Profit or Loss” shall have the meaning set forth in Section 8.5.

     “Co-Promotion Net Sales” shall mean Gross Sales less (a) sales returns and accruals for
allowances, including trade, quantity and cash discounts and any other adjustments, including those
granted on account of price adjustments, billing errors, rejected goods, damaged goods, returns,
rebates, chargeback rebates, fees, reimbursements or similar payments granted or given to
wholesalers or other distributors (including specialty pharmaceutical companies who act as
distributors), buying groups, healthcare insurance carriers or other institutions, (b) any payment
in respect of sales to any Governmental or Regulatory Authority in respect of any government
subsidized program, including and without limitation Medicare and Medicaid rebates, and (c) any
item substantially similar in character and/or substance to the above, all as determined in
accordance with GAAP on a basis consistent with Bayer’s annual audited financial statements. In
addition, Co-Promotion Net Sales by Bayer hereunder are subject to the following:

     (1) In the case of any sale or other disposal of a Co-Promotion Collaboration Product
by Bayer to an Affiliate, for resale, the Co-Promotion Net Sales shall be calculated as
above on the value charged or invoiced on the first arm’s length sale to a Third Party; and

     (2) [ * ]

     “Co-Promotion Program” shall mean the annual plan for the promotion, marketing and sale of the
Co-Promotion Collaboration Product as developed by the JMC and approved by the Executive Committee.
The Co-Promotion Program shall set forth the manner in which the Co-Promotion Collaboration
Product is to be promoted and marketed in the United States during the period to which the
Co-Promotion Program relates and shall include, at a minimum: (a) [ * ]; (b) [ * ]; (c) [ * ]; (d)
[ * ]; (e) [ * ]; (f) [ * ]; (g) [ * ]; (h) [ * ]; (i) [ * ]; (j) [ * ]; and (k) [ * ].

     “Co-Promotion Selling and Promotion Expenses” shall mean all costs (excluding Allocable
Co-Promotion Overhead Costs or any other overhead costs) incurred consistent with the Budget in the
Co-Promotion Program, and specifically identifiable to the sales and/or promotion of the
Co-Promotion Collaboration Product in the United States, including all costs associated with (a) [
* ]; (b) [ * ]; and (c) [ * ]. Co-Promotion Selling and Promotion Expenses shall exclude Sales
Force Expenses and MSL Expenses.

     “CRM System” shall mean a customer relationship management system utilized in connection with
the tracking of sales activity relating to the Co-Promotion Collaboration Product in the United
States.

     “Detail” or “Detailing” shall mean each separate face-to-face contact by a sales
representative with a Target Healthcare Professional during which time the promotional message
involving the Co-Promotion Collaboration Product is presented and is a principal topic of
discussion.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

5

 

     “Development Payments” shall mean those payments specified in Section 11.8 of the
Collaboration Agreement.

     “Direct Claim” shall have the meaning set forth in Section 12.4(a).

     “Dispute” shall have the meaning set forth in Article XV.

     “Equivalent Sales FTE” shall mean a Sales FTE equivalent as determined under the standards and
methods adopted by the Executive Committee under Section 3.1(g) hereof, which standards and methods
will establish the means for measuring the performance required of a Sales FTE deployed to market
multiple products in addition to his or her marketing and sale of Co-Promotion Collaboration
Product.

     “Executive Committee” or “EC” shall mean that committee described and set forth in Section
3.1, which was originally organized as the JRDC under the Collaboration Agreement and which has
been renamed the Executive Committee.

     “FDA” shall mean the United States Food and Drug Administration or any successor entity
thereto.

     “Force Majeure Event” shall have the meaning set forth in Section 16.10.

     “GAAP” shall mean United States generally accepted accounting principles, as may be amended
from time to time.

     “Good Manufacturing Practices” shall mean the current standards for manufacture, as set forth
in the Act and applicable regulations and guidelines promulgated thereunder or any successor
thereto, as shall be in effect from time to time during the Term.

     “Governmental or Regulatory Authority” shall mean any court, tribunal, arbitrator, agency,
commission, official or other instrumentality of any government or of any federal, state, county,
city or other political subdivision thereof, including without limitation the FDA.

     “Gross Sales” shall mean the amount of sales of Co-Promotion Collaboration Product in the
United States invoiced by Bayer, its Affiliates, subcontractors and permitted sublicensees to Third
Parties, in accordance with GAAP. For timing purposes, Gross Sales shall be recognized in
accordance with the revenue recognition policies utilized by Bayer for financial reporting
purposes.

     “Indemnifiable Losses” shall mean liabilities, losses, damages or other amounts payable to a
Third Party claimant, as well as any reasonable attorneys’ fees and costs of litigation incurred by
either the Bayer Indemnified Party or the Onyx Indemnified Party, as the case may be, in connection
with any Claim.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

6

 

     “Joint Development Committee” or “JDC” shall mean that joint development Sub-Committee
operating under delegated authority of the Executive Committee under Section 3.3(h) of the
Collaboration Agreement.

     “Joint Finance Committee” or “JFC” shall mean that joint finance Sub-Committee operating under
delegated authority of the Executive Committee under Section 3.3(h) of the Collaboration Agreement.

     “Joint Marketing Committee” or “JMC” shall mean that committee described and set forth in
Section 3.2.

     “Joint Profit and Loss Statement” shall have the meaning set forth in Section 8.2.

     “Limited Recall” shall have the meaning set forth in Section 7.4(a).

     “Losses” shall mean liabilities, losses, damages, as well as any reasonable attorneys’ fees
and costs of litigation, incurred by a party.

     “LMR” shall mean Bayer’s Legal Medical Regulatory review team.

     “Marketing Materials” shall have the meaning set forth in Section 6.2(a).

     “Material Breach” shall have the meaning set forth in Section 10.3(a).

     “Marketing FTE Expenses” shall mean the aggregate of all salary and benefits expenses for a
full-time equivalent (based on a full-time equivalent year of 2,080 hours, inclusive of vacation
time and holidays) marketing personnel [ * ].

     “MSL Expenses” shall mean those costs that are identified below and that are incurred by a
party beginning [ * ], in each case consistent with and specifically identifiable to the
establishment and maintenance of medical affairs personnel (including MSLs and medical affairs
field directors) to the extent such personnel are, or will be, assigned to supporting Co-Promotion
Collaboration Product in the United States: (a) [ * ]; (b) [ * ]; (c) [ * ]; (d) [ * ]; (e) [ * ];
and (f) [ * ].

     “MMA” shall have the meaning set forth in Section 12.8(d).

     “MSLs” shall mean the medical science liaisons to be appointed by each party.

     “NDA” shall mean (a) the single application or set of applications for the Co-Promotion
Collaboration Product filed by Bayer with the FDA or any successor agency having the administrative
authority to regulate the approval for marketing of new human pharmaceutical products, delivery
systems and devices in the United States, and (b) any related registrations with or notifications
to the FDA.

     “Non-Publishing Party” shall have the meaning set forth in Section 16.8.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

7

 

     “Non-Serious Adverse Event” shall mean any adverse drug experience associated with the use of
the Co-Promotion Collaboration Product in humans, whether or not considered drug-related, which is
not a Serious Adverse Event.

     “Notice of Termination For Material Breach” shall have the meaning set forth in Section
10.3(c).

     “Notifying Party” shall have the meaning set forth in Section 10.2(a).

     “OIG” shall mean the Office of the Inspector General.

     “Onyx” shall have the meaning set forth in the Preamble of this Agreement.

     “Onyx Indemnified Party” shall have the meaning set forth in Section 12.2(a).

     “PDMA” shall mean the Prescription Drug Marketing Act of 1987, Title 21 of the U.S. Code of
Federal Regulations, Parts 203 and 205, as amended, and any final regulations or guidances
promulgated thereunder from time-to-time.

     “Performance Qualifications” shall mean those qualifications for the Sales FTEs reasonably
established from time to time by the JMC.

     “Permanent Recall” shall have the meaning set forth in Section 7.4(a).

     “Person” shall mean an individual, corporation, partnership, limited liability company, trust,
business trust, association, joint stock company, joint venture, pool, syndicate, sole
proprietorship, unincorporated organization, governmental authority, or any other form of entity
not specifically listed herein.

     “Pharmacovigilance Agreement” shall have the meaning set forth in Section 7.5.

     “PhRMA Code” shall mean the Pharmaceutical Research and Manufacturers of America Code on
Interactions with Healthcare Professionals, as hereafter amended from time to time.

     “Product Liability Claim” shall have the meaning set forth in Section 12.3(e).

     “Product Technical Complaint” shall mean any complaint that questions the purity, identity,
potency or quality of the Co-Promotion Collaboration Product, its packaging or labeling or the
compliance of any batch of the Co-Promotion Collaboration Product with Applicable Laws including
current Good Manufacturing Practices; any complaint that concerns any incident that causes the
Co-Promotion Collaboration Product or its labeling to be mistaken for, or applied to, another
article; any bacteriological contamination or significant chemical, physical or other change or
deterioration in the Co-Promotion Collaboration Product; any failure of one or more batches of the
Co-Promotion Collaboration Product to meet the specifications therefor in the NDA; or any complaint
or evidence of tampering with the Co-Promotion Collaboration Product.

     “Publishing Party” shall have the meaning set forth in Section 16.8.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

8

 

     “Recall” shall have the meaning set forth in Section 7.4(a).

     “Regulatory Approval Date” shall mean the date of receipt of United States Regulatory Approval
with respect to the Co-Promotion Collaboration Product, December 20, 2005.

     “Sales Force Expenses” shall mean those costs that are identified below and that are incurred
by a party beginning [ * ], in each case consistent with and specifically identifiable to the
establishment and maintenance of sales personnel (including a field-based sales force and regional
managers) to the extent such personnel are, or will be, assigned to selling Co-Promotion
Collaboration Product in the United States: (a) [ * ]; (b) [ * ]; (c) [ * ]; (d) [ * ]; (e) [ * ];
and (f) [ * ].

     “Sales FTE” shall mean a full-time equivalent (based on a full-time equivalent year of 2,080
hours, inclusive of vacation time and holidays) field-based pharmaceutical sales representative,
district sales manager, or sales trainer who promotes a Co-Promotion Collaboration Product in the
United States during the Term and who satisfies each of the following criteria:

	 	(1)	 	[ * ];
	 
	 	(2)	 	[ * ];
	 
	 	(3)	 	[ * ];
	 
	 	(4)	 	[ * ]; and
	 
	 	(5)	 	[ * ].

     “SEC” shall mean the United States Securities and Exchange Commission.

     “Serious Adverse Event” shall mean any serious and unexpected adverse drug experience, as
defined in 21 C.F.R. Section 314.80 or Section 312.32, associated with the use of the Co-Promotion
Collaboration Product in humans, whether or not considered drug-related.

     “Sub-Committees” shall mean the JDC, the JFC and the JMC, and any other sub-committee(s)
appointed by the Executive Committee from time to time pursuant to Section 3.3(h) of the
Collaboration Agreement; any reference to a committee or sub-committee in this Agreement shall
refer to an existing Sub-Committee.

     “Target Healthcare Professionals” shall mean physicians who are cancer specialists,
radiologists or other prescribers of oncology therapeutics, including persons lawfully influencing
(or in a position to lawfully influence) the opinions of such persons, in each case who are
authorized by Applicable Laws to prescribe the Co-Promotion Collaboration Product.

     “Term” shall have the meaning set forth in Section 10.1.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

9

 

     “Third Party” shall mean any person or entity other than Bayer or Onyx, or an Affiliate of
either of them.

     “United States” shall mean the United States of America, its territories and possessions.

     “United States Regulatory Approval” shall mean approval by the FDA or any successor entity of
an NDA or other applicable filing and satisfaction of any related applicable FDA registration and
notification requirements (if any), together with any pricing approvals and labeling approvals.

     “US COGS” shall mean, for sales of the Co-Promotion Collaboration Product in the United States, [ * ]

     “US Sublicense Revenues” shall mean all revenues received from Third Parties as consideration
for the sublicensing of the manufacture, use and/or sale of the Co-Promotion Collaboration Product
in the United States.

     “US Third Party Royalties” shall mean those royalties payable to a Third Party in respect of
the import, sale, offer for sale, use or manufacture of the Co-Promotion Collaboration Product in
the United States.

     “Weighted Average” shall mean X where X= [ * ] ÷ m, and where:

n1 is the number of [ * ];

d1 is the number of [ * ];

n2 is the number of [ * ];

d2 is the number of [ * ];

d1 + d2 shall [ * ]; and

m is the aggregate number of [ * ].

     For example: If the Co-Promotion Program requires that each party [ * ], the Weighted
Average would equal:

[ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

10

 

ARTICLE II

GRANTS OF RIGHTS

     Section 2.1 Co-Promotion Rights Relating to the Co-Promotion Collaboration Product.

          (a) Pursuant to Section 13.4 of the Collaboration Agreement, Onyx has exercised its option to
Co-Promote the Co-Promotion Collaboration Product in the United States. Subject only to Onyx’s
compliance with the terms and conditions of the Collaboration Agreement relating to payment of
one-half of the Co-Development Costs incurred worldwide for such Co-Promotion Collaboration Product
(excluding Japan), Onyx has the right, on an exclusive basis together with Bayer, to Co-Promote the
Co-Promotion Collaboration Product in the United States during the Term, upon and subject to the
terms and conditions set forth in this Agreement.

          (b) Subject only to Onyx’s compliance with the terms and conditions of the Collaboration
Agreement relating to payment of one-half of the Co-Development Costs incurred worldwide for such
Co-Promotion Collaboration Product (excluding Japan), Bayer hereby undertakes its rights to
Co-Promote the Co-Promotion Collaboration Product in the United States together with Onyx during
the Term, upon and subject to the terms and conditions set forth in this Agreement.

     Section 2.2 Co-Promotion Rights of other Collaboration Products, if any. Notwithstanding
anything to the contrary contained herein, Onyx shall retain an option, pursuant to Section 13.4 of
the Collaboration Agreement, to co-promote in the United States any other Collaboration Product (as
such term is defined in the Collaboration Agreement) that receives United States Regulatory
Approval, provided Onyx has paid one-half of the Co-Development Costs incurred worldwide for such
Collaboration Product (excluding Japan). If Onyx exercises its right to co-promote another such
Collaboration Product, the parties shall confer and enter into a separate definitive agreement
substantially similar to this Agreement pertaining to such other Collaboration Product.

ARTICLE III

MANAGEMENT

     Section 3.1 Overview. The parties, by mutual consent, have treated the JRDC (as defined in
the Collaboration Agreement) as the Executive Committee since the first two (2) calendar quarters
of 2004 (the “Executive Committee” or “EC”). The activities of the parties under the Collaboration
Agreement and this Agreement shall also be supervised and managed by the Executive Committee in
accordance with the procedural and governance provisions of the Collaboration Agreement (as it may
be hereafter amended from time to time). Nothing contained in this Agreement shall be construed to
expand the authority of the Executive Committee. The Executive Committee shall perform the
specific functions set forth in the Collaboration Agreement and in this Agreement, including the
following additional general tasks in connection with the management of the Co-Promotion:

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

11

 

               (a) determine the overall strategy for the Co-Promotion in the manner contemplated by this
Agreement;

               (b) review and approve the Co-Promotion Program and Budget and all Co-Promotion Marketing
Expenses;

               (c) assess and determine if any Third Party technology should be acquired or licensed for
purposes of commercialization of the Co-Promotion Collaboration Product;

               (d) establish and delegate duties and responsibilities to other sub-committees on an
“as-needed” basis to oversee particular projects or activities, including without limitation the
Sub-Committees, by resolution without amending this Agreement or the Collaboration Agreement,
pursuant to its powers under Section 3.3(h) of the Collaboration Agreement;

               (e) oversee and approve the activities of the Sub-Committees;

               (f) address disputes and disagreements arising in the Sub-Committees;

               (g) if either party desires to utilize its Sales FTEs for the marketing and sale of one or
more additional products with the Co-Promotion Collaboration Product, the EC shall determine [ * ]
the number of Sales FTEs such party would be required to use to promote said multiple products so
that such party’s allocation of Sales FTE effort promoting the Co-Promotion Collaboration Product
is equivalent to the number of Sales FTEs for that party as was set by the EC. Notwithstanding the
foregoing, in the event the Executive Committee is unable to reach agreement within [ * ] as to
such [ * ], then [ * ] within [ * ], [ * ]. Such [ * ] shall [ * ] and shall [ * ]. Such party
shall rely on the [ * ] to ensure that its allocation of Sales FTE effort promoting the
Co-Promotion Collaboration Product is equivalent to the number of Sales FTEs for that party as set
by the EC; and

               (h) perform any other functions as appropriate to further the purposes of this Agreement as
expressly set forth herein or as otherwise determined by the parties.

     Section 3.2 Joint Marketing Committee.

          (a) Formation and Membership. The Joint Marketing Committee (the “JMC”) shall consist of up
to six (6) members, with up to three (3) each appointed by Onyx and Bayer, provided that one (1)
member of each party will be a Vice-President of Sales and/or Marketing, or equivalent thereto, for
such party. In the event the Executive Committee shall decide at any time to disband the JMC, all
powers and delegated authority of the JMC shall automatically revert, without further action, to
the Executive Committee. Notwithstanding anything to the contrary contained herein, the authority
of the JMC shall be limited to the authority conferred upon it by the Executive Committee; nothing
contained in this Agreement shall be construed to permanently fix or establish the powers and
duties of the JMC, and the Executive Committee shall be free to expand or contract the powers
conferred upon the JMC

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

12

 

from time to time. Members of the JMC shall be composed of senior executives of each party
authorized to make decisions with respect to the matters within the scope of the JMC’s authority.
An alternate member designated by a party may serve temporarily in the absence of a permanent
member designated by such party. Each party shall appoint and replace its representatives to the
JMC, as appropriate during the Co-Promotion.

          (b) Functions and Powers of the Joint Marketing Committee. The Co-Promotion activities of the
parties under this Agreement shall be supervised and managed by the JMC. The JMC shall perform the
specific functions set forth in this Agreement, and in addition shall perform the following general
tasks in managing the Co-Promotion:

               (i) prepare the Co-Promotion Program and Budget for submission to the Executive Committee on
an annual basis not later than [ * ];

               (ii) oversee implementation of the Co-Promotion Program and Budget;

               (iii) direct and oversee all marketing activities concerning the Co-Promotion Collaboration
Product (whether conducted directly by the parties or through Third Party vendors);

               (iv) prepare the sales strategy for the Co-Promotion Collaboration Product, including the
development of the Call Plan (if applicable);

               (v) establish and delegate duties to other Sub-Committees on an “as-needed” basis for purposes
of advising the JMC as to matters within its responsibilities; and

               (vi) perform any other functions as appropriate to further the purposes of this Agreement as
determined by the provisions hereof or by the Executive Committee.

     Section 3.3 Committee Decision Making. Subject to the terms of Section 3.2 above, the JMC
shall take action by unanimous vote with each party having a single vote, irrespective of the
number of such party’s representatives actually in attendance. The members of the JMC shall act in
good faith to cooperate with one another to reach agreement with respect to issues to be decided by
the Sub-Committee. If the JMC is unable to reach unanimous consent on any matter over which the
JMC has authority within [ * ] of the first consideration of such matter, the matter shall be
referred to the Executive Committee for decision.

     Section 3.4 Obligations of the Parties. Onyx and Bayer shall provide the Executive Committee
and the Joint Marketing Committee and their authorized representatives with reasonable access
during regular business hours to all records, documents and information relating to this
Co-Promotion which such Committee may reasonably require in order to perform its obligations
hereunder, provided that if such records, documents and information are under a bona fide
obligation of confidentiality to a Third Party, then Onyx or Bayer, as the case may be, may
withhold access thereto to the extent necessary to satisfy such obligation. In addition, the
parties agree to exercise Commercially Reasonable Efforts to provide one another with reasonable
contractual rights of access to all such Third Party records, documents and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

13

 

information in connection with the execution of new (or amended) Third Party contracts entered
into from time to time during the Term.

ARTICLE IV

RESPONSIBILITIES OF ONYX

     Section 4.1 Promotion of the Co-Promotion Collaboration Product by Onyx.

          (a) Throughout the Term, Onyx shall contribute fifty percent (50%) of the overall number of
Sales FTEs required by the Co-Promotion Program as developed by the JMC and approved by the
Executive Committee. Onyx shall use its Commercially Reasonable Efforts to market and promote the
Co-Promotion Collaboration Product to Target Healthcare Professionals in the United States in
accordance with the then-current Co-Promotion Program, and shall perform additional services
assigned to it from time to time by the Executive Committee. Subject to Section 4.1(b), the exact
number of Sales FTEs to be provided by Onyx will be determined by the JMC and approved by the
Executive Committee and established under and pursuant to the Co-Promotion Program.

          (b) (i) Onyx shall provide a minimum Weighted Average of not less than [ * ] of all [ * ]
assigned to Onyx in each [ * ] of each [ * ] of the Term. In the event that Onyx provides less
than a Weighted Average of [ * ] of all [ * ] assigned to Onyx for any given [ * ] following the
first Contract Year (based on the Weighted Average number of [ * ] for each [ * ] of the relevant [
* ], on an average basis), then Onyx shall incur a [ * ] calculated as follows:

     [ * ]

Any [ * ] due and payable under this Section will be due to Bayer no later than thirty (30) days
following the expiration of the [ * ] that gave rise to the [ * ]. In the event that the parties
disagree whether Onyx has satisfied its obligation to provide a Weighted Average of [ * ] of all [
* ] assigned to Onyx in the given period, the matter shall be reviewed by the JFC for up to [ * ]
days in an attempt to resolve the matter. In the event the JFC cannot resolve the issue within
such time period, either party shall be entitled to submit the issue to the Executive Committee for
resolution pursuant to Article 25 of the Collaboration Agreement.

               (ii) Onyx shall provide at least [ * ] of the [ * ] for each [ * ] period beginning on each
anniversary of commercial launch of the Co-Promotion Collaboration Product. The initial [ * ]
shall be equal to the [ * ]. In each case the Onyx sales force fails to meet [ * ] of the [ * ]
for a [ * ], Onyx shall [ * ] of the applicable Sales FTE rate for such year. The determination of
whether the [ * ] have been met shall be measured within [ * ] days following each anniversary of a
commercial launch, and shall begin on the second anniversary of the commercial launch. For
clarity, the [ * ] provided in this Section 4.1(b)(ii) shall be additive to the [ * ] set forth in
Section 4.1(b)(i).

          (c) Unless the parties otherwise agree, Onyx shall provide fifty percent (50%) of the overall
number of MSLs required by the Co-Promotion Program to support the Co-

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

14

 

Promotion Collaboration Product, and Onyx shall be solely responsible for 100% of its own MSL
Expenses, unless otherwise provided under Section 8.4(a) below.

          (d) The MSLs provided by Onyx, together with the MSLs provided by Bayer, shall develop for
approval by the JMC an integrated medical affairs program and policies thereto approved by the MSLs
of each party that includes [ * ] from the appropriate MSLs to any query from the field or from
either party.

          (e) In performing its duties hereunder, Onyx shall, and shall cause its employees to: (i) [ *
]; and (ii) [ * ]. No employee of Onyx shall make any representation, statement, warranty or
guaranty with respect to the Co-Promotion Collaboration Product that is not consistent with current
labeling of the Co-Promotion Collaboration Product or Marketing Materials developed in conformity
with Section 6.2(a) hereof, that is deceptive or misleading or that disparages the Co-Promotion
Collaboration Products or the good name, goodwill and reputation of Bayer. Onyx shall use
Commercially Reasonable Efforts to ensure that its services delivered pursuant to this Agreement
will be provided in a professional, ethical and competent manner.

     Section 4.2 CRM System and Sales/Prescriber Data. Bayer shall [ * ] exercise Commercially
Reasonable Efforts to [ * ] to the CRM System with [ * ] to include Onyx as a licensee and
subscriber. Such [ * ] shall provide that Bayer and Onyx shall be [ * ] to the CRM System and to [
* ] related to the Co-Promotion Collaboration Product. Notwithstanding the foregoing, each party’s
sales representatives shall be responsible for providing information on an ongoing basis as
requested in the CRM System, including without limitation [ * ] information. Information contained
in the CRM System pertaining to Onyx shall be treated as Confidential Information of Onyx and shall
not be used or disclosed to Third Parties without Onyx’s prior written approval or direction,
unless otherwise required by Applicable Laws.

     Section 4.3 Onyx Sales Force.

          (a) The parties agree, for purposes of this Agreement, that each Sales FTE shall initially be
assigned a Sales FTE rate of [ * ], which rate is based upon Bayer’s and Onyx’s [ * ]. The Sales
FTE rate shall be adjusted annually by the Executive Committee in connection with the approval of
the Budget and shall be [ * ]; provided, however, that in the event the Executive
Committee is unable to adjust the Sales FTE rate by [ * ] of the calendar year preceding the
adjustment year due to any deadlock of the Executive Committee, the Sales FTE rate shall be
adjusted to reflect any [ * ]. Onyx shall be solely responsible for all of its own Sales Force
Expenses in promoting the Co-Promotion Collaboration Product, unless otherwise provided under
Section 8.4(a) below. Each Sales FTE of Onyx shall be an employee of Onyx and shall remain under
the direct and exclusive authority, supervision and control of Onyx at all times during the Term.
Onyx shall supervise and maintain such competent and qualified sales representatives as may be
required to promote the Co-Promotion Collaboration Product as provided herein and in the
Co-Promotion Program and shall cause the sales force to meet the Performance Qualifications. In
the event that Onyx commences sales of another product using the same sales force as used to
promote the Co-Promotion Collaboration Product, Onyx shall still

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

15

 

be obligated to satisfy its obligations hereunder, including without limitation to provide its
minimum number of Equivalent Sales FTEs required to promote the Co-Promotion Collaboration Product.
Onyx shall not [ * ] without the prior approval of the Executive Committee. For the period
commencing on the Co-Promotion Effective Date and for [ * ] thereafter, Onyx shall [ * ];
provided, however, that (subject to Section 4.1(a)) Sales FTEs may be added or
removed at the discretion of Onyx.

          (b) Subject to Section 6.2(a), all written, electronic and visual communications provided to
any of Onyx’s sales representatives regarding strategy, positioning or selling messages for the
Co-Promotion Collaboration Product will be subject to review and approval by the [ * ] to ensure
uniform messaging and execution. The costs and expenses of providing such written, electronic and
visual communications shall be considered Allowable Co-Promotion Expenses.

ARTICLE V

RESPONSIBILITIES OF BAYER

     Section 5.1 Promotion of the Co-Promotion Collaboration Product by Bayer.

          (a) Throughout the Term, Bayer shall contribute fifty percent (50%) of the overall number of
Sales FTEs required by the Co-Promotion Program as developed by the JMC and approved by the
Executive Committee. Bayer shall use its Commercially Reasonable Efforts to market and promote the
Co-Promotion Collaboration Product to Target Healthcare Professionals in the United States in
accordance with the then-current Co-Promotion Program, and shall perform additional services
assigned to it from time to time by the Executive Committee. Subject to Section 5.1(b), the exact
number of Sales FTEs to be provided by Bayer will be determined by the JMC and approved by the
Executive Committee and established under and pursuant to the Co-Promotion Program.

          (b) (i) Bayer shall provide a minimum Weighted Average of not less than [ * ] of all [ * ]
assigned to Bayer in each [ * ] of [ * ] of the Term. In the event that Bayer provides less than a
Weighted Average of [ * ] of all [ * ] assigned to Bayer for any given [ * ] following the first
Contract Year (based on the Weighted Average number of [ * ] for each [ * ] of the relevant [ * ]
on an average basis), then Bayer shall incur a [ * ] calculated as follows:

     [ * ]

Any [ * ] due and payable under this Section will be due to Onyx no later than thirty (30) days
following the expiration of the [ * ] that gave rise to the [ * ]. In the event that the parties
disagree whether Bayer has satisfied its obligation to provide a Weighted Average of [ * ] of all [
* ] assigned to Bayer in the given period, the matter shall be reviewed by the JFC for up to [ * ]
days in an attempt to resolve the matter. In the event the JFC cannot resolve the issue within
such time period, either party shall be entitled to submit the issue to the Executive Committee for
resolution pursuant to Article 25 of the Collaboration Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

16

 

               (ii) Bayer shall provide at least [ * ] of the [ * ] for each [ * ] period beginning on each
anniversary of commercial launch of the Co-Promotion Collaboration Product. The initial [ * ]
shall be equal to the [ * ]. In each case the Bayer sales force fails to meet [ * ] of the [ * ]
for a [ * ], Bayer shall [ * ] of the applicable Sales FTE rate for such year. The determination
of whether the [ * ] have been met shall be measured within [ * ] following each anniversary of a
commercial launch, and shall begin on the second anniversary of the commercial launch. For
clarity, the [ * ] provided in this Section 5.1(b)(ii) shall be additive to the [ * ] set forth in
Section 5.1(b)(i).

          (c) Unless the parties otherwise agree, Bayer shall provide fifty percent (50%) of the overall
number of MSLs required by the Co-Promotion Program to support the Co-Promotion Collaboration
Product, and Bayer shall be solely responsible for 100% of its own MSL Expenses, unless otherwise
provided under Section 8.4(a) below.

          (d) The MSLs provided by Bayer, together with the MSLs provided by Onyx, shall develop for
approval by the JMC an integrated medical affairs program and policies thereto approved by the MSLs
and the Regional Sales Manager of each party that includes [ * ] from the appropriate MSLs to any
query from the field or from either party.

          (e) In performing its duties hereunder, Bayer shall, and shall cause its employees to: (i) [ *
]; and (ii) [ * ]. No employee of Bayer shall make any representation, statement, warranty or
guaranty with respect to the Co-Promotion Collaboration Product that is not consistent with current
labeling of the Co-Promotion Collaboration Product or Marketing Materials developed in conformity
with Section 6.2(a) hereof, that is deceptive or misleading or that disparages the Co-Promotion
Collaboration Products or the good name, goodwill and reputation of Onyx. Bayer shall use
Commercially Reasonable Efforts to ensure that its services delivered pursuant to this Agreement
will be provided in a professional, ethical and competent manner.

          (f) In the event the Executive Committee decides to promote the Co-Promotion Collaboration
Product to healthcare professionals in the [ * ] field, [ * ] shall be included in such promotion
activities. The Executive Committee shall determine the appropriate weighting of such sales
effort, taking into consideration the [ * ]. Under such circumstances, other promotion activities
undertaken by Bayer and Onyx related to the Co-Promotion Collaboration Product shall then be
adjusted in order to maintain equality in overall sales efforts by each party.

     Section 5.2 CRM System and Sales/Prescriber Data. As set forth in Section 4.2 above, Bayer
shall [ * ] exercise Commercially Reasonable Efforts to [ * ] to the CRM System with [ * ] to
include Onyx as a licensee and subscriber. Such [ * ] shall provide that Bayer and Onyx shall be [
* ] to the CRM System and to [ * ] related to the Co-Promotion Collaboration Product.
Notwithstanding the foregoing, each party’s sales representatives shall be responsible for
providing information on an ongoing basis as requested in the CRM System, including without
limitation [ * ] information. Information contained in the CRM System pertaining to Bayer shall be
treated as Confidential Information of Bayer and shall not be used or disclosed to

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

17

 

Third Parties without Bayer’s prior written approval or direction, unless otherwise required
by Applicable Laws.

     Section 5.3 Bayer Sales Force.

          (a) The parties agree, as specified in Section 4.3 above, each Sales FTE shall initially be
assigned a Sales FTE value of [ * ], which rate is based upon Bayer’s and Onyx’s [ * ]. The Sales
FTE rate shall be adjusted annually by the Executive Committee in connection with the approval of
the Budget and shall be the [ * ]; provided, however, that in the event the
Executive Committee is unable to adjust the Sales FTE rate by [ * ] of the calendar year preceding
the adjustment year due to any deadlock of the Executive Committee, the Sales FTE rate shall be
adjusted to reflect any [ * ]. Bayer shall be solely responsible for all of its own Sales Force
Expenses in promoting the Co-Promotion Collaboration Product, unless otherwise provided under
Section 8.4(a) below. Each Sales FTE of Bayer shall be an employee of Bayer and shall remain under
the direct and exclusive authority, supervision and control of Bayer at all times during the Term.
Bayer shall supervise and maintain such competent and qualified sales representatives as may be
required to promote the Co-Promotion Collaboration Product as provided herein and in the
Co-Promotion Program and shall cause the sales force to meet the Performance Qualifications. In
the event that Bayer commences sales of another product using the same sales force as used to
promote the Co-Promotion Collaboration Product, Bayer shall still be obligated to satisfy its
obligations hereunder, including without limitation to provide its minimum number of Equivalent
Sales FTEs required to promote the Co-Promotion Collaboration Product. Bayer shall not [ * ]
without the prior approval of the Executive Committee. For the period commencing on the
Co-Promotion Effective Date and for [ * ] months thereafter, Bayer shall [ * ]; provided,
however, that (subject to Section 5.1(a)) Sales FTEs may be added or removed at the
discretion of Bayer.

          (b) Subject to Section 6.2(a), all written, electronic and visual communications provided to
any of Bayer’s sales representatives regarding strategy, positioning or selling messages for the
Co-Promotion Collaboration Product will be subject to review and approval by the [ * ] to ensure
uniform messaging and execution. The costs and expenses of providing such written, electronic and
visual communications shall be considered Allowable Co-Promotion Expenses.

     Section 5.4 Manufacture, Shipment, Booking, Invoicing, etc. of the Co-Promotion Collaboration
Product.

          (a) Bayer (and/or its Affiliates) shall have the sole responsibility for the manufacture,
shipment, distribution, warehousing, sale, invoicing, order entry and acknowledgement with regard
to sales of the Co-Promotion Collaboration Product, for the collection of receivables resulting
from sales of the Co-Promotion Collaboration Product in the United States, and for recording of
Collaboration Revenue in Bayer’s electronic sales activity tracking system. If for any reason Onyx
receives orders for Co-Promotion Collaboration Products, Onyx shall immediately and accurately
forward such orders to Bayer (or, if so directed by Bayer, to Bayer’s wholesalers) as soon as
practicable.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

18

 

          (b) Bayer shall manufacture and supply all Co-Promotion Collaboration Product for the United
States pursuant to Article 19 of the Collaboration Agreement. Bayer shall manufacture such
Co-Promotion Collaboration Product in accordance with Good Manufacturing Practices and any other
applicable regulatory or legal requirements. All Co-Promotion Collaboration Products supplied by
Bayer shall conform to all then-applicable specifications set forth in the United States Regulatory
Approval for the Co-Promotion Collaboration Products. Bayer shall annually review the fixed and
variable unit costs of such Co-Promotion Collaboration Product and shall advise the Executive
Committee of [ * ].

          (c) Onyx may make recommendations to the Executive Committee from time to time regarding
pricing strategies for the Co-Promotion Collaboration Product in the United States during the Term.
The Executive Committee may make recommendations to Bayer from time to time regarding pricing
strategies for the Co-Promotion Collaboration Product during the Term. Notwithstanding
recommendations received from the Executive Committee, Bayer shall have the sole, exclusive and
final authority to determine the price of the Co-Promotion Collaboration Product during the Term,
including price increases and decreases and the timing thereof. Notwithstanding the foregoing,
nothing contained in this Section 5.4(c) shall be construed to modify or amend Bayer’s general
obligations as set forth in the last sentence of Section 13.12 of the Collaboration Agreement.

          (d) In addition to the foregoing, Bayer will use Commercially Reasonable Efforts during the
Term to provide the following services in relation to the parties’ marketing and sale of the
Co-Promotion Collaboration Product: (i) [ * ]; (ii) [ * ]; (iii) [ * ]; (iv) [ * ]; (v) [ * ];
(vi) [ * ]; (vii) [ * ]; (viii) [ * ]; (ix) [ * ]; (x) [ * ]; and (xi) [ * ] (collectively, the
“Bayer Marketing Services”). As further set forth in Section 8.9, the Budget for each Contract
Year shall provide for the [ * ] for each of the components of the Bayer Marketing Services (as
described in subclauses (i) through (xi) above), and Bayer agrees to charge, as compensation for
the Bayer Marketing Services, [ * ] of the annual amount specified by the Budget for such Bayer
Marketing Services during the Contract Year in question. Any disputes regarding the allocation
methodology or the amount to be budgeted for the Bayer Marketing Services in connection with the
marketing and sale of the Co-Promotion Collaboration Product shall be resolved by the Executive
Committee (and, in the absence of such resolution, in the manner specified by Article XV hereof);
provided, however, that Bayer reserves the right to [ * ] of the Bayer Marketing Services in the [
* ] as to the [ * ]. Onyx covenants and agrees that (except as expressly provided in this Section
5.4(d)), unless otherwise agreed by the parties, Onyx will [ * ].

ARTICLE VI

EMPLOYEES; TRAINING AND MARKETING MATERIALS

     Section 6.1 Compensation of Sales Representatives. The Executive Committee (or any duly
constituted sub-committee thereof) shall adopt an annual plan providing for incentive compensation
awards and performance metrics attributable to the sale of the Co-Promotion Collaboration Product.
Such annual incentive compensation plans shall be applicable to [ * ]. Notwithstanding the
foregoing, each party shall [ * ] to its own sales representatives, and each

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

19

 

party may, [ * ], provide additional [ * ] offered to sales representatives in the
pharmaceutical industry. Either party may also provide [ * ] to its sales representatives.

          (a) Each of the parties agrees to make its sales representatives and MSLs available for
Co-Promotion Collaboration Product training with respect to the marketing and sale of the
Co-Promotion Collaboration Product. Bayer and Onyx shall [ * ] on the content and curriculum of
Co-Promotion Collaboration Product training programs for each of Onyx’s and Bayer’s sales forces
and MSLs subject [ * ] to [ * ] of all training program content and materials and separately to [ *
] prior to implementation of such training programs. Bayer and Onyx shall [ * ] in Co-Promotion
Collaboration Product training materials developed hereunder; provided, however,
that such training materials may not be used by either party in any manner inconsistent with the
express terms and conditions of this Agreement without the consent of the other party.

          (b) Each of the parties shall conduct such Co-Promotion Collaboration Product training of its
own sales force and of its own MSLs. If the parties decide to conduct joint training of their
sales forces and MSLs, then such Co-Promotion Collaboration Product training shall be carried out
at such time(s) and location(s) as agreed upon by the parties from time to time. As additional
members are added to the parties’ respective sales forces and MSL teams responsible for marketing
and supporting the Co-Promotion Collaboration Product, training will be given to groups of the
newly added members. Unless the parties otherwise agree, the costs of [ * ] for the parties’
personnel for all such Co-Promotion Collaboration Product-specific training shall be a Sales Force
Expense and/or MSL Expense, with each party solely responsible for its own expenses related
thereto.

          (c) Each of Bayer and Onyx agrees to provide regular healthcare compliance training to its
employees involved in the sales, marketing, promotion of, or price reporting for, the Co-Promotion
Collaboration Product as appropriate and necessary that meets the training requirements and
standards established by the JMC, and that will, at a minimum, cover the content and frequency of
the training required by the [ * ].

     Section 6.2 Marketing Materials.

          (a) The JMC shall direct and approve the development of all sales, promotion and advertising
materials, regardless of form (“Marketing Materials”), relating to the Co-Promotion Collaboration
Product; provided, however, that the form and content of said marketing materials
shall be subject to [ * ]. The parties shall jointly own all right, title and interest in all
Marketing Materials. Notwithstanding the foregoing, nothing contained in this Section 6.2(a) shall
be construed to override, amend, modify or restate Bayer’s right to determine the global marketing
strategy and message for the Co-Promotion Collaboration Product under Sections 13.1 and 13.2 of the
Collaboration Agreement.

          (b) Whenever Marketing Materials are presented and described to the medical community
(including, for example, the physician, pharmacy, governmental, reimbursement and hospital
sectors), the parties will be presented and described as joining in the promotion of the
Co-Promotion Collaboration Product in the United States. All Marketing Materials will state this

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

20

 

arrangement and will display the names and logos of the parties with [ * ], as and to the
extent permitted by Applicable Laws.

          (c) Each party will exercise Commercially Reasonable Efforts to ensure that its Sales FTEs and
MSLs: (i) do not modify, alter, amend, adjust or mask any portion of the Marketing Materials in any
way, and (ii) do not use or distribute any marketing materials other than the Marketing Materials
approved by the parties for use in connection with the marketing and sale of the Co-Promotion
Collaboration Product hereunder. Each party will promptly notify the other party and take all
necessary corrective action in the event a party learns that any such modification, alteration,
amendment, adjustment or masking, or any such use or distribution of unapproved marketing materials
has taken place. In addition, each party reserves the right to [ * ] who cause such party to [ * ]
of this Agreement.

          (d) Each party will exercise Commercially Reasonable Efforts to follow all plans and
directives of the Executive Committee (or any duly constituted Sub-Committee thereof) concerning
marketing, and any and all related activities, including without limitation any such plans and
directives related to the Call Plan (if applicable) and the appropriate Target Healthcare
Professionals in connection with the marketing and sale of the Co-Promotion Collaboration Product.

     Section 6.3 [ * ] of Employees. The parties hereby agree that, [ * ] neither will, directly
or indirectly, [ * ]; provided, however, that the [ * ] shall not be deemed to
violate the foregoing provision.

     Section 6.4 Promotion of [ * ]. The parties’ respective sales forces responsible for
marketing the Co-Promotion Collaboration Product shall not market a [ * ] without the prior written
consent of the other party.

ARTICLE VII

REGULATORY MATTERS

     Section 7.1 Licenses. Each party hereto shall, at its sole cost and expense, maintain in full
force and effect all necessary licenses, permits and other authorizations required by contract
and/or by Applicable Laws to carry out its duties and obligations under this Agreement.

     Section 7.2 Labeling and Marketing Materials. No Co-Promotion Collaboration Product labeling,
package inserts, monographs, packaging for the Co-Promotion Collaboration Product or Marketing
Materials may be used or distributed by the parties unless such labeling, package inserts,
monographs, packaging for the Co-Promotion Collaboration Products or Marketing Materials have been
approved in advance in accordance with Section 6.2(a) hereof.

     Section 7.3 Efficacy and Safety Information. Bayer shall furnish Onyx with efficacy and
safety information reasonably requested by Onyx to assist Onyx in promoting the Co-Promotion
Collaboration Product to Target Healthcare Professionals in the United States, including without
limitation relevant clinical and safety data included in the NDA for the Co-

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

21

 

Promotion Collaboration Product and additional information, if any, related to the efficacy
and safety profile of the Co-Promotion Collaboration Product.

     Section 7.4 Recalls.

          (a) Each party shall promptly notify the other party in writing if it determines that any
event, incident or circumstance has occurred which may result in the need for a “recall” or “market
withdrawal,” as such terms are defined in 21 C.F.R. Part 7.3, of the Co-Promotion Collaboration
Product in the United States (“Permanent Recall”) or a “recall” or “market withdrawal”, as such
terms are defined in 21 C.F.R. Part 7.3, of the Co-Promotion Collaboration Product in the United
States that is limited in territory or as to any lot(s) or batches of the Co-Promotion
Collaboration Product (“Limited Recall” and collectively with Permanent Recall, a “Recall”).

          (b) If either party gives a notice described in Section 7.4(a), and [ * ], the Executive
Committee will immediately meet and confer regarding the advisability of a Recall (which conference
may be in the form of a telephone conference or video conference). If [ * ], the Executive
Committee may provide its recommendation to [ * ] on the course of action preferred by that
Committee. Notwithstanding the foregoing, nothing contained herein shall be construed to imply any
right of [ * ], to consent to any decision by [ * ] to discontinue, temporarily or permanently or
on a limited basis, the distribution and sale of the Co-Promotion Collaboration Product. [ * ]
will have sole responsibility for and will make all decisions with respect to any recall, market
withdrawal, or any other corrective action of similar nature related to the Co-Promotion
Collaboration Product. [ * ] shall be solely responsible for interactions with the FDA or other
Governmental and Regulatory Authorities with regard to any such corrective action, except that [ *
] may take such actions as may be required of it by Applicable Laws. In all matters subject to this
Section 7.4(b): (i) [ * ] shall notify and consult with [ * ] as promptly as reasonably practicable
taking into account all relevant circumstances, and (ii) if [ * ] decides that a Recall is
necessary, it will notify the [ * ] by telephone or in writing in advance of initiating or publicly
announcing such Recall.

          (c) If [ * ] makes a determination that a Limited Recall of the Co-Promotion Collaboration
Product is necessary but [ * ] disagrees with such determination, [ * ] may initiate a joint
discussion by the parties of such issue with [ * ] within [ * ] days of such determination, and
such [ * ] shall make its decision within a reasonable period of time not to exceed [ * ] days of
the [ * ] receipt of notice of the determination. If such [ * ] advises the parties that [ * ]
believes there should be a Limited Recall, the parties shall voluntarily implement a Limited Recall
of the Co-Promotion Collaboration Product.

          (d) If [ * ] makes a determination that a Permanent Recall of the Co-Promotion Collaboration
Product is necessary but [ * ] disagrees with such determination, [ * ] shall have the right to [ *
] with respect to the Co-Promotion Collaboration Product and to [ * ] with respect to the
Co-Promotion Collaboration Product. In such case, [ * ] in the [ * ]. [ * ] shall thereafter have
exclusive authority and control over the commercialization of Co-Promotion Collaboration Product in
the [ * ]. [ * ] shall thereafter receive [ * ] realized from the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

22

 

sale of Co-Promotion Collaboration Product [ * ]. Such [ * ] arrangement shall continue until
[ * ], and the provisions of Sections 16.7 through 16.13 of the Collaboration Agreement shall apply
to such payments.

          (e) Any documented, direct, out-of-pocket costs paid or accrued by a party with respect to
participating in such Recall, market withdrawal, or other corrective action will be an [ * ];
provided, however that if such recall, market withdrawal or other corrective action
was caused by (i) a party’s negligence, malfeasance, or willful misconduct occurring while the
Co-Promotion Collaboration Product was under such party’s control, or (ii) a Material Breach, such
party will reimburse the other for such costs and they will not be deemed [ * ].

     Section 7.5 Pharmacovigilance Agreement. Promptly after the Co-Promotion Effective Date, the
parties shall exercise Commercially Reasonable Efforts to execute a [ * ] pharmacovigilance
agreement (the “Pharmacovigilance Agreement”). The Pharmacovigilance Agreement shall provide for,
but not be limited to, the exchange of (i) [ * ]; (ii) [ * ]; (iii) [ * ]; (iv) [ * ]; (v) [ * ];
(vi) [ * ]; and (vii) [ * ].

     Section 7.6 Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for
Human Use. Bayer’s LMR will be solely responsible for submitting, recording and storing all FDA
2253 submissions.

ARTICLE VIII

ECONOMICS OF CO-PROMOTION; PROFIT SHARING

     Section 8.1 Overview. Pursuant to this Agreement, Onyx and Bayer shall share equally in the
Co-Promotion Marketing Profit or Loss, as the case may be, generated by the promotion of
Co-Promotion Collaboration Products in the United States. As described more fully below, the
Co-Promotion Marketing Profit or Loss shall be determined pursuant to a Joint Profit and Loss
Statement, as described in Section 8.2, that will detail the Allowable Co-Promotion Expenses to be
deducted from Co-Promotion Net Sales in calculating Co-Promotion Marketing Profit or Loss.
Following such calculation, Co-Promotion Marketing Profit or Loss shall be allocated fifty percent
(50%) to each party. As further described in (and subject to) Section 8.8 below, following the
allocation of Co-Promotion Marketing Profit between Bayer and Onyx and the subsequent deduction of
one-half of the aggregate Sales Force Expenses, MSL Expenses and Co-Development Costs incurred by
Onyx and Bayer, Bayer shall continue to be entitled to reduce payments of Co-Promotion Marketing
Profit otherwise due Onyx hereunder by the amount of any special distribution as repayment of
Development Payments made by Bayer to Onyx under the Collaboration Agreement.

     Section 8.2 Joint Profit and Loss Statement. The reporting and determination (subject to the
provisions of this Article VIII) of Co-Promotion Marketing Profit or Loss under this Agreement
shall be governed by a joint profit and loss statement (the “Joint Profit and Loss Statement”) to
be prepared by [ * ]. Such Joint Profit and Loss Statement shall be prepared and delivered
consistent with the provisions of Sections 8.3, 8.4 and 8.5 hereof, and all other relevant terms
and conditions of this Agreement, and shall be approved by the Executive Committee.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

23

 

     Section 8.3 Reporting Sales. Bayer shall report to Onyx and to the Executive Committee sales
of Co-Promotion Collaboration Products in the following manner:

          (a) [ * ], Bayer shall report Gross Sales of Co-Promotion Collaboration Product made in the
United States for [ * ];

          (b) Within [ * ] days of the end of each of the [ * ] of each Contract Year, Bayer shall
report Co-Promotion Net Sales accrued in the United States for Co-Promotion Collaboration Product
for the preceding [ * ]; and

          (c) Within [ * ] days of the end of the [ * ] of each Contract Year, Bayer shall report
Co-Promotion Net Sales accrued in the United States for Co-Promotion Collaboration Product for the
[ * ].

     Section 8.4 Allowable Expenses.

          (a) Commencing for the Contract Year that begins on the Co-Promotion Effective Date, and
within [ * ] days of the end of each calendar month thereafter and within [ * ] days of the end of
each Contract Year thereafter, each party shall provide the other party with a [ * ] report of that
party’s Allowable Co-Promotion Expenses incurred (each, an “Allowable Expense Report”) setting
forth the following information relating to the [ * ] and comparisons of such information to the
then-current Co-Promotion Program and Budget: the party’s Allowable Co-Promotion Expenses showing
each specific type of cost included in the definition of Allowable Co-Promotion Expenses separately
and listing the project relating to each such cost, if applicable. Each party shall be solely
responsible for its own Sales Force Expenses and MSL Expenses in promoting the Co-Promotion
Collaboration Product, unless otherwise approved by the Executive Committee and each of the parties
agree that the parties have been solely responsible for their own Sales Force Expenses and MSL
Expenses since [ * ]. Notwithstanding the foregoing, if the parties decide to reallocate
responsibility for providing Sales FTEs and/or MSLs so that one party provides less than fifty
percent (50%) of the overall number of Sales FTEs and/or MSLs required, then the party providing
fewer than half of the overall Sales FTEs and/or MSLs shall [ * ] (provided,
however, that nothing contained in this Section 8.4(a) shall be construed to entitle either
party to [ * ] of Sales FTEs or MSLs at a [ * ] that established from time to time by the Executive
Committee). The [ * ] made pursuant to the foregoing sentence with respect to Sales FTEs shall [ *
]: (i) [ * ] and (ii) [ * ]. The [ * ] made pursuant to the foregoing sentence with respect to
MSLs shall [ * ]: (i) [ * ] and (ii) [ * ].

          (b) Each such Allowable Expense Report shall be delivered in a mutually-agreeable electronic
format to the extent possible or in hard copy form. Each Allowable Expense Report shall be treated
as Confidential Information of the reporting party and, subject to Applicable Laws, shall not be
disclosed to Third Parties without such party’s prior written approval or direction.
Notwithstanding the foregoing, nothing contained in this Agreement shall prevent either party from
using the data in any Allowable Expense Reports in connection with its compliance with its price
reporting obligations under Applicable Laws (provided, however, that each party shall use
Commercially Reasonable Efforts to protect Confidential Information of the other party).

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

24

 

          (c) The expenses included in the Joint Profit and Loss Statement and submitted by each party
shall [ * ] or [ * ], and all such expenses shall be incurred pursuant to and consistent with the
Co-Promotion Program and Budget or as otherwise determined by the Executive Committee.
Notwithstanding the foregoing, nothing contained herein shall be construed to imply that either
party shall [ * ].

     Section 8.5 Determination of Marketing Profit and Loss. Within [ * ] days following the end
of each of the [ * ] of each Contract Year and [ * ] days following the end of the [ * ] of each
Contract Year, Bayer shall determine and allocate Co-Promotion Marketing Profit or Loss, according
to the Joint Profit and Loss Statement to be approved by the Executive Committee under Section 8.2,
by subtracting from Collaboration Revenue the Allowable Co-Promotion Expenses.

The result of such calculation shall be deemed “Co-Promotion Marketing Profit or Loss.” In the
event of any dispute regarding these items, the matter shall be reviewed by the JFC for up to [ * ]
days in an attempt to resolve the matter. In the event the JFC cannot resolve the issue within
such time period, either party shall be entitled to submit the issue for resolution pursuant to
Article 25 of the Collaboration Agreement.

     Section 8.6 Allocation of Marketing Profit and Loss and Related Payments.

          (a) The Co-Promotion Marketing Profit or Loss, as the case may be, shall be divided equally
between Bayer and Onyx.

          (b) If there is a Co-Promotion Marketing Profit for such quarter, then Bayer shall make
payment to Onyx within [ * ] days of the end of each quarter and within [ * ] days of the end of
each Contract Year so that each party will receive an equal share of the Co-Promotion Marketing
Profit for such quarter, after giving effect to the Co-Promotion Net Sales invoiced by Bayer, any
US Sublicense Revenue, and the Allowable Co-Promotion Expenses borne by each party. By way of
example, if in a particular calendar quarter there was a Co-Promotion Marketing Profit of [ * ],
and during such quarter Onyx incurred Allowable Co-Promotion Expense of [ * ], the balancing
payment pursuant to this Section 8.6(b) would be a payment by [ * ] which represents reimbursement
of Onyx’s Allowable Co-Promotion Expense plus Onyx’s fifty percent share (50%) of the Co-Promotion
Marketing Profit.

          (c) If there is a Co-Promotion Marketing Loss for such quarter, then one party shall make a
payment to the other party within [ * ] days of the end of each quarter and within [ * ] days of
the end of each Contract Year so that each party will bear an equal share of the Co-Promotion
Marketing Loss for such quarter after giving effect to the Co-Promotion Net Sales invoiced by
Bayer, any US Sublicense Revenues, and the Allowable Co-Promotion Expenses borne by each party. By
way of example, if in a particular calendar quarter there was a Co-Promotion Marketing Loss of [ *
], and during such quarter Onyx incurred Allowable Co-Promotion Expenses of [ * ], the balancing
payment pursuant to this Section 8.6(c) would be a payment by [ * ], which represents Onyx’s fifty
percent (50%) share of the Co-Promotion Marketing Loss, less reimbursement of Onyx’s Allowable
Co-Promotion Expenses.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

25

 

     Section 8.7 [ * ]. On a periodic basis as [ * ] available to Bayer, Bayer shall [ * ]
included within Co-Promotion Net Sales, US Sublicense Revenues, and/or Allowable Co-Promotion
Expenses to reflect the [ * ] then available.

     Section 8.8 Reimbursement of Development Payments. Pursuant to Section 16.3 of the
Collaboration Agreement, within [ * ] days after the end of the relevant calendar quarter, Bayer
shall be entitled to receive a special distribution from Onyx as reimbursement for Development
Payments made by Bayer to Onyx under the Collaboration Agreement. The amount of such special
distribution, including the mechanics of its calculation and payment, shall be governed by Section
16.3 of the Collaboration Agreement; provided, however, that a) Marketing Profit
(as calculated pursuant to the terms of the Collaboration Agreement) shall be calculated instead on
the basis of Co-Promotion Marketing Profit or Loss of Co-Promotion Collaboration Product in the
United States (as determined under this Agreement) [ * ], shall still apply. Bayer shall be
entitled to offset any payment due Onyx under Section 8.6 of this Agreement against any Development
Payment due from Onyx under Section 16.3 of the Collaboration Agreement.

     Section 8.9 Budget. The Budget for each Contract Year (including the first Contract Year)
shall be prepared by the JMC and a first draft thereof shall be submitted to the Executive
Committee (or any duly constituted sub-committee thereof charged with such authority by the
Executive Committee) by [ * ] of the preceding Contract Year. In the event the Executive
Committee, following review and deliberation, cannot agree upon the relevant Budget prior to [ * ]
in respect of the next Contract Year, the Executive Committee shall [ * ] for which agreement is
achieved and shall [ * ] for which agreement was not achieved, except that the parties shall [ * ]
an amount equal to the [ * ].

     Section 8.10 Royalties. The parties agree that nothing contained in this Agreement shall be
construed to affect the parties’ respective royalty rights and obligations set forth in Section
16.2 of the Collaboration Agreement.

     Section 8.11 Federal and State Tax Characterization. The parties agree that nothing contained
in this Agreement shall be construed to affect the parties’ respective rights and obligations set
forth in Article 23 of the Collaboration Agreement. The tax characterization, procedures,
calculations, documentation, filings and other requirements provided for in Article 23 of the
Collaboration Agreement shall be applied and carried out, mutatis mutandis, with respect to this
Agreement.

ARTICLE IX

RECORDKEEPING AND AUDITS

     Section 9.1 Audits. The parties recognize that audits and reviews of records are in the best
interests of both parties. The parties shall have the audit rights in respect of any and all
calculations and accounting function provided for in this Agreement under and in conformity with
the provisions of Section 17.2 of the Collaboration Agreement.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

26

 

     Section 9.2 Maintenance of Books and Records. Each party shall maintain complete and accurate
books and records in sufficient detail, in accordance with GAAP and all Applicable Laws, to enable
verification of the performance of such party’s obligations under this Agreement. Such records
shall be maintained for a period of [ * ] years after the creation or generation of such records,
or longer if required by Applicable Laws.

     Section 9.3 Compliance Audits. In addition to the access and audit rights of Bayer and Onyx
provided for in Section 17.2 of the Collaboration Agreement, upon reasonable prior notice from the
other party and no more than [ * ] during any Contract Year during the Term, each party shall
afford to the other party reasonable access during normal business hours (and at such other times
as the parties may mutually agree) to inspect and audit the relevant books, records and other
information of such party in order to monitor such party’s compliance with such party’s call
activity and other relevant obligations under the Co-Promotion Program and the terms of this
Agreement, to the extent such party is responsible for the relevant function as directed by the
Executive Committee or the terms of this Agreement, and for the purposes of determining compliance
with Applicable Laws and the terms of this Agreement. Any inspection conducted by either party
pursuant to this Section 9.3 shall be at the sole cost and expense of such party.

ARTICLE X

TERM AND TERMINATION

     Section 10.1 Term of Agreement. This Agreement shall commence as of the Co-Promotion
Effective Date and, unless sooner terminated as provided herein or in the Collaboration Agreement,
shall continue in effect until the first to occur of the following: (i) the date that Co-Promotion
Collaboration Products are no longer sold by either party in the United States due to a permanent
product withdrawal or recall or a voluntary decision by the parties to abandon the Co-Promotion of
the Co-Promotion Collaboration Products in the United States, or (ii) the effective date of any
termination of the Collaboration Agreement under Article 24 thereof (the “Term”).

     Section 10.2 Breaches (General).

          (a) If either party (the “Breaching Party”) shall have committed a breach of this Agreement,
the other party (the “Notifying Party”) shall provide written notice of such breach to the
Breaching Party. For all allegations of breach other than an allegation of Material Breach (as
defined below in Section 10.3), the parties hereby agree that they shall seek to resolve the matter
during the notice and cure period provided in Section 10.2(b) and may thereafter invoke other
remedies available to it in law or equity as provided for in Section 12.4 below and in Article 25
of the Collaboration Agreement.

          (b) Upon receipt of a notice of breach other than a Material Breach, the alleged Breaching
Party shall have [ * ] days within which to cure such breach following receipt of such notice;
provided, however, if the breach is capable of being cured but cannot be reasonably cured in such [
* ]-day period, then the alleged Breaching Party shall have such additional time as necessary to
cure the breach if the alleged Breaching Party (i) during such [ *]-day

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

27

 

period has submitted a plan that, if successfully carried out, would be effective in
curing such breach, and has commenced its execution of such plan, and (ii) diligently pursues such
plan thereafter. If the matter is not resolved to the satisfaction of the Notifying Party during
the foregoing cure period, then the Notifying Party may invoke the provisions of Article 25 of the
Collaboration Agreement with respect to claims for damages, attorneys’ fees and court costs and
requests for equitable relief, but the Notifying Party shall have no right to terminate this
Agreement for such breach.

          (c) The Notifying Party may, at its discretion, resort to the dispute resolution mechanisms of
Article 25 of the Collaboration Agreement, and may invoke all available remedies in law or equity
other than termination of this Agreement, without invoking the mechanisms of Section 10.3.

     Section 10.3 Allegations of Material Breach.

          (a) The parties intend that this Agreement shall survive breaches not constituting Material
Breaches, and shall not be terminable for breaches unless the breach in question: (i) [ * ]; or
(ii) [ * ] (each, a “Material Breach”). In the event there is a dispute as to whether a Material
Breach has occurred, this Agreement shall survive pending a determination pursuant to Article 25 of
the Collaboration Agreement that a Material Breach has occurred.

          (b) If a party believes that a Material Breach has occurred (or will occur in the event such
breach is determined to exist), it shall give written notice to the Breaching Party of the nature
of the breach and the reason the Notifying Party believes it is a Material Breach. The alleged
Breaching Party shall then have a period of [ * ] days following receipt of such notice in which to
cure the breach; provided, however, if the Material Breach is capable of being cured but cannot be
reasonably cured in such [ * ]-day period, then the alleged Breaching Party shall have such
additional time as necessary to cure the breach if the alleged Breaching Party (i) during such [ *
]-period has submitted a plan that, if successfully carried out, would be effective in curing such
Material Breach, and has commenced its execution of such plan, and (ii) diligently pursues such
plan thereafter. Any such notice of alleged Material Breach by the Notifying Party shall include a
reasonably detailed description of all relevant facts and circumstances demonstrating, supporting
and/or relating to each such alleged Material Breach by the Breaching Party.

          (c) If the alleged Material Breach is not cured within the cure period specified in Section
10.3(b), the Notifying Party may give notice of termination (“Notice of Termination For Material
Breach”). If the Breaching Party agrees that a Material Breach has occurred and was not cured
within the cure period, then the Parties shall proceed to terminate this Agreement. If the
Breaching Party does not agree that a Material Breach has occurred and was not cured within the
cure period, then this Agreement shall survive, and the parties shall continue to perform their
obligations hereunder, until the issue of whether there has been an uncured Material Breach by the
Breaching Party is resolved in accordance with Article 25 of the Collaboration Agreement. In lieu
of bringing a separate action, either party may elect to petition the court under Article 25 of the
Collaboration Agreement for an advance declaration that a

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

28

 

breach, if found, constitutes a Material Breach hereunder, and the parties agree to waive any
procedural objection to such declaratory petition and action by the relevant court.

          (d) If the Notifying Party gives Notice of Termination For Material Breach, and it is later
determined by a court pursuant to Article 25 of the Collaboration Agreement that in fact there has
not been an uncured Material Breach by the Breaching Party, then this Agreement shall continue in
full force and effect.

     Section 10.4 Termination of Collaboration Agreement. This Agreement shall automatically
terminate, without notice to or from any party, upon any termination of the Collaboration Agreement
under any of the conditions set forth therein; provided however, if there is a
dispute as to whether a party has the right to terminate the Collaboration Agreement, such dispute
shall be resolved in the same manner as any other claim of material breach thereof.
Notwithstanding anything to the contrary contained herein, the parties expressly agree that Section
24.4 of the Collaboration Agreement will continue in full force and effect.

     Section 10.5 Effects of Termination.

          (a) Neither the termination nor expiration of this Agreement shall release or operate to
discharge either party from any liability or obligation that may have accrued prior to such
termination or expiration. Any termination of this Agreement as provided herein shall not be an
exclusive remedy but shall be in addition to any remedies whatsoever that may be available to the
terminating party.

          (b) Notwithstanding the giving of any notice of termination pursuant to this Article X, each
party shall continue to fulfill its obligations under this Agreement at all times until the
effective date of any such termination.

          (c) In the event of any termination of this Agreement in conformity with its terms, the
termination shall have following effect:

	 	(i)	 	[ * ]
	 
	 	(ii)	 	[ * ]

     Section 10.6 Survival. The representations, warranties, covenants and agreements of the
parties in Article I, Article IX, Section 10.5, Section 10.6 and Articles XI through XVI hereof,
and all provisions relating to Confidential Information shall survive any expiration or termination
of this Agreement. In addition, any provision of this Agreement that, either from the express
language or the context thereof, is intended to survive any termination or expiration of this
Agreement shall survive any such expiration or termination.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

29

 

ARTICLE XI

CONFIDENTIALITY

     All Confidential Information provided by one party to the other under and pursuant to this
Agreement shall be considered, and shall be protected under, the provisions of Article 22 of the
Collaboration Agreement.

ARTICLE XII

INDEMNIFICATION AND INSURANCE; LIMITATION OF LIABILITY

     Section 12.1 Indemnification by Onyx.

          (a) In each case, other than with respect to Product Liability Claims (the treatment of which
is governed exclusively by Section 12.3 of this Agreement) and Claims of infringement (the
treatment of which is governed exclusively by Article 21 of the Collaboration Agreement), Onyx
shall defend, indemnify and hold harmless Bayer and its Affiliates and each of their officers,
directors, shareholders, employees, successors and assigns (each a “Bayer Indemnified Party”) from
and against all Claims of Third Parties, and all associated Indemnifiable Losses, incurred or
suffered by any of them to the extent resulting from or arising out of:

               (i) the breach by Onyx or any of its Affiliates of any of its representations, warranties or
covenants in this Agreement; and

               (ii) the negligent acts or negligent omissions or willful misconduct by Onyx or any of its
Affiliates in the performance of any of their obligations under this Agreement.

               Notwithstanding the foregoing, no Bayer Indemnified Party shall be entitled to any
indemnification pursuant to this Section 12.1, to the extent the Indemnifiable Loss for which
indemnification is being sought is caused by the negligent acts or negligent omissions or willful
misconduct or willful violation of Applicable Laws of any Bayer Indemnified Party.

          (b) Bayer shall give Onyx prompt written notice of any Claim for which it seeks to be
indemnified under this Section 12.1, but the omission of such notice shall not relieve Onyx from
its obligations under this Section 12.1, except to the extent Onyx can establish actual prejudice
and direct damages as a result thereof. Onyx shall have no obligation under this Section 12.1 with
respect to any Claim unless:

               (i) Onyx is granted full authority and control over the defense, including, without
limitation, settlement, of such Claim, and

               (ii) Bayer cooperates fully with Onyx and its agents in defense of such Claim.

          (c) Bayer shall have the right to participate in the defense of any such Claim utilizing
attorneys of its choice, at its own expense. Subject to the remainder of this subsection,

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

30

 

Onyx shall have full authority and control to handle the Claim for which Bayer seeks
indemnification under this Section 12.1. Any settlement of the Claim that would admit liability on
the part of any Bayer Indemnified Party, or that would involve any relief (including the payment of
money damages), shall be subject to Bayer’s prior written approval, such approval not to be
unreasonably withheld or delayed.

          (d) In the event of the institution of any Claim by a Third Party against Bayer or any of its
Affiliates arising out of the alleged violation by Onyx of any [ * ], Onyx shall defend, indemnify
and hold harmless each of the Bayer Indemnified Parties from and against such Claim, and all
associated Indemnifiable Losses to the extent arising out of such alleged violation by Onyx.

     Section 12.2 Indemnification by Bayer.

          (a) In each case, other than with respect to Product Liability Claims (the treatment of which
is governed exclusively by Section 12.3 of this Agreement) and Claims of infringement (the
treatment of which is governed exclusively by Article 21 of the Collaboration Agreement), Bayer
shall defend, indemnify and hold harmless Onyx and its Affiliates and each of their officers,
directors, shareholders, employees, successors and assigns (each an “Onyx Indemnified Party”) from
and against all Claims of Third Parties, and all associated Indemnifiable Losses, incurred or
suffered by any of them to the extent resulting from or arising out of:

               (i) the breach by Bayer or any of its Affiliates of any of its representations, warranties or
covenants in this Agreement;

               (ii) the negligent acts or negligent omissions or willful misconduct by Bayer or any of its
Affiliates in the performance of any of their obligations under this Agreement; and

               (iii) any liability, costs, or expense to the extent arising out of or related to the
calculation by Bayer of the sales price for the Co-Promotion Collaboration Products.

          Notwithstanding the foregoing, no Onyx Indemnified Party shall be entitled to any
indemnification pursuant to this Section 12.2 to the extent the Indemnifiable Loss for which
indemnification is being sought is caused by the negligent acts or negligent omissions or willful
misconduct or willful violation of Applicable Law of any Onyx Indemnified Party.

          (b) Onyx shall give Bayer prompt written notice of any Claim for which it seeks to be
indemnified under this Section 12.2, but the omission of such notice shall not relieve Bayer from
its obligations under this Section 12.2, except to the extent Bayer can establish actual prejudice
and direct damages as a result thereof. Bayer shall have no obligation under this Section 12.2
with respect to any Claim unless:

               (i) Bayer is granted full authority and control over the defense, including, without
limitation, settlement, of such Claim, and

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

31

 

               (ii) Onyx cooperates fully with Bayer and its agents in defense of such Claim.

          (c) Onyx shall have the right to participate in the defense of any such Claim utilizing
attorneys of its choice, at its own expense. Subject to the remainder of this subsection, Bayer
shall have full authority and control to handle the Claim for which Onyx seeks indemnification
under this Section 12.2. Any settlement of the Claim that would admit liability on the part of any
Onyx Indemnified Party, or that would involve any relief (including the payment of money damages),
shall be subject to Onyx’s prior written approval, such approval not to be unreasonably withheld or
delayed.

          (d) In the event of the institution of any Claim by a Third Party against Onyx or any of its
Affiliates arising out of the alleged violation by Bayer of any [ * ], Bayer shall defend,
indemnify and hold harmless each of the Onyx Indemnified Parties from and against such Claim, and
all associated Indemnifiable Losses to the extent arising out of such alleged violation by Bayer.

     Section 12.3 Product Liability Claims.

          (a) Bayer shall be solely responsible for all Indemnifiable Losses arising out of or relating
to all Claims of Third Parties for personal injury, death or other Co-Promotion Collaboration
Product liability, and all associated Indemnifiable Losses, to the extent Onyx can establish that
such personal injury, death or other Co-Promotion Collaboration Product liability and all
associated Indemnifiable Losses were caused by (i) Bayer’s negligent acts or omissions, or willful
misconduct (including, without limitation, any willful breach of this Agreement), or (ii) the
manufacturing, marketing, promotion or other commercialization of the Co-Promotion Collaboration
Product by Bayer in a manner that is unlawful or inconsistent with the approved Co-Promotion
Collaboration Product labeling for such Co-Promotion Collaboration Product; provided, however, that
in no event shall Bayer be liable hereunder to the extent any such Claim arises out of Bayer’s
promotion of the Co-Promotion Collaboration Product in accordance with approved Co-Promotion
Collaboration Product labels and such Claim is based on a theory of failure to warn.

          (b) Onyx shall be solely responsible for all Indemnifiable Losses arising out of or relating
to all Claims of Third Parties for personal injury, death or other Co-Promotion Collaboration
Product liability, and all associated Indemnifiable Losses, to the extent Bayer can establish that
such personal injury, death or other Co-Promotion Collaboration Product liability and all
associated Indemnifiable Losses were caused by (i) Onyx’s negligent acts or omissions, or willful
misconduct (including, without limitation, any willful breach of this Agreement), or (ii) the
marketing, promotion or other commercialization of the Co-Promotion Collaboration Product by Onyx
in a manner that is unlawful or inconsistent with the approved Co-Promotion Collaboration Product
labeling for such Co-Promotion Collaboration Product; provided, however, that in no event shall
Onyx be liable hereunder to the extent any such Claim arises out of Onyx’s promotion of the
Co-Promotion Collaboration Product in accordance with approved

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

32

 

Co-Promotion Collaboration Product labels and such Claim is based on a theory of failure to
warn.

          (c) In addition to the obligations set forth in Section 12.2, Bayer shall defend, indemnify
and hold harmless each of the Onyx Indemnified Parties from and against all Claims of Third Parties
for personal injury, death or other Co-Promotion Collaboration Product liability, and all
associated Indemnifiable Losses, for which Bayer is responsible under Section 12.3(a).

          (d) In addition to the obligations set forth in Section 12.1, Onyx shall defend, indemnify and
hold harmless each of the Bayer Indemnified Parties from and against all Claims of Third Parties
for personal injury, death or other Co-Promotion Collaboration Product liability, and all
associated Indemnifiable Losses, for which Onyx is responsible under Section 12.3(b).

          (e) Each of Bayer and Onyx shall give the other prompt written notice of any Claims within the
scope of Sections 12.3(c) or 12.3(d) (each a “Product Liability Claim”), but the omission of such
notice shall not relieve any party from its obligations under this Section 12.3, except to the
extent the other party can establish actual prejudice and direct damages as a result thereof. With
respect to each Product Liability Claim, the party who is responsible for indemnifying the other
party against such Product Liability Claim pursuant to Section 12.3(c) or Section 12.3(d), as
applicable, shall assume the lead role in the defense of such Product Liability Claim (the
“Controlling Party”). The Controlling Party shall consult with the other party on all material
aspects of the defense, including, without limitation, settlement, of such Product Liability Claim,
and the other party shall have a full opportunity to participate in decision-making with respect to
the strategy of such defense, and both parties shall cooperate fully with each other in connection
therewith. The non-defending party shall also have the right to participate in the defense of any
Product Liability Claim, utilizing attorneys of its choice, at its own expense. In furtherance of
the parties’ cooperation, the Controlling Party will consult with the other party regarding
strategic decisions, including, without limitation, the retention of counsel and defense of each
Product Liability Claim. The Controlling Party will otherwise keep the other party fully informed
of the status and progress of the defense and any settlement discussions concerning the Product
Liability Claim. The settlement of a Product Liability Claim that would admit liability on the
part of any party or its Affiliates, that would involve any relief other than the payment of money
damages within a budget previously agreed to by the parties, or that would not include a full and
unconditional release of the parties subject thereto shall be subject to the prior written approval
of such parties, such approval not to be unreasonably withheld or delayed.

          (f) Losses arising out of or relating to Claims of Third Parties for personal injury, death or
other Co-Promotion Collaboration Product liabilities that are not covered by Sections 12.3(a) or
12.3(b) (such as Losses arising from a failure to warn) shall be shared by the parties as Allowable
Co-Promotion Expenses (or, in the event of any termination of this Agreement under Sections 7.4(d)
or 10.5(c)(i) or (ii) hereof, deducted by the party paying the royalties or payments described
thereunder).

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

33

 

     Section 12.4 Direct Claims.

          (a) Any Claim made directly by a party (the “Asserting Party”) against a Breaching Party
following the date hereof on account of Losses that do not result from a Claim of a Third Party but
do result from or arise out of a breach by the Breaching Party of its representations and
warranties or covenants under this Agreement (a “Direct Claim”) may be asserted at any time prior
to the expiration of the statute of limitations related to such Claim, by giving the Breaching
Party written notice thereof. Such notice by the Asserting Party will describe the basis of the
Direct Claim (including reasonable detail of the particulars of the alleged breach) and will
indicate the estimated amount, if reasonably practicable, of Losses that have been or may be
sustained by the Asserting Party. Thereafter, the Asserting Party shall deliver to the Breaching
Party, as promptly as reasonably practicable, such materials as the Asserting Party reasonably
believes provides the underlying support for the Direct Claim; it being understood that in no event
will the Asserting Party be required to provide information which is subject to attorney-client
privilege or other applicable privilege or that is the subject of a written obligation of
confidentiality to a Third Party in existence at the time of the Asserting Party’s Claim. The
Breaching Party shall respond in writing to a Direct Claim within [ * ] calendar days of receipt of
the Asserting Party’s notice. If the Breaching Party does not so respond within such [ * ] day
period, the Breaching Party will be deemed to have rejected such Direct Claim. If the Breaching
Party rejects such Claim, in whole or in part, or is deemed to have rejected such Direct Claim, the
Asserting Party will be free to pursue such remedies as may be available to the Asserting Party on
the terms and subject to the provisions of this Agreement. Notwithstanding the foregoing, a
failure by a party to give timely notice or response or to include any specified information in any
notice or response as provided in this Section 12.4 shall not relieve any other party from its
obligations hereunder, except to the extent the other party can establish actual prejudice and
direct damages as a result thereof.

          (b) In no event will Bayer be entitled to recover Losses arising out of Direct Claims from
Onyx or any of its Affiliates arising out of a breach by Onyx or any of its Affiliates of any of
its representations and warranties or covenants contained in this Agreement until [ * ] amount of
all Claims for Losses under this Section 12.4 for breaches of representations and warranties or
covenants [ * ], in which event Onyx will be liable to the full extent of such Losses.

          (c) In no event will Onyx be entitled to recover Losses arising out of Direct Claims from
Bayer or any of its Affiliates arising out of a breach by Bayer or any of its Affiliates of any of
its representations and warranties or covenants contained in this Agreement until [ * ] amount of
all Claims for Losses under this Section 12.4 for breaches of representations and warranties or
covenants [ * ], in which event Bayer will be liable to the full extent of such Losses.

          (d) The parties hereby agree that, unless resulting from a party’s fraudulent behavior, the
sole and exclusive remedies available to an Asserting Party arising out of a Direct Claim shall be
such remedies available under the law of contracts. The parties further agree that neither Onyx
nor Bayer shall be entitled to pursue, and hereby expressly waive, any and all rights that may
otherwise be available under the law of torts.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

34

 

     Section 12.5 Insurance. From and after the Co-Promotion Effective Date and for a period of [
* ] years after the expiration of this Agreement or the earlier termination of this Agreement,
Bayer and Onyx shall each obtain and/or maintain, respectively, at its sole cost and expense,
product liability insurance (including any self-insured arrangements) in amounts, respectively,
which are reasonable and customary in the pharmaceutical industry in the United States for
companies of comparable size and activities at the respective place of business of such party.
Such product liability insurance or self-insured arrangements shall insure against all liability,
including, without limitation, personal injury, physical injury, or property damage arising out of
the manufacture, sale, distribution, or marketing of the Co-Promotion Collaboration Products. Each
party shall provide to the other, upon request of the other party, a certificate of insurance
verifying the existence of such insurance.

     Section 12.6 Limitation of Liability. NOTWITHSTANDING ANY OTHER PROVISION CONTAINED HEREIN, [
* ], IN NO EVENT SHALL BAYER, ON THE ONE HAND, OR ONYX, ON THE OTHER HAND, BE LIABLE TO THE OTHER
OR ANY OF THE OTHER PARTY’S AFFILIATES FOR ANY [ * ] DAMAGES SUFFERED OR INCURRED BY SUCH OTHER
PARTY OR ITS AFFILIATES IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT OR THE
COLLABORATION AGREEMENT. IN ADDITION, DAMAGES SHALL [ * ] BY A PARTY OR ITS AFFILIATES FOR LOSS
THAT THE OTHER PARTY OR ITS AFFILIATES [ * ] AND IN NO EVENT SHALL BAYER, ON THE ONE HAND, OR ONYX,
ON THE OTHER HAND, BE LIABLE TO THE OTHER OR ANY OF THE OTHER PARTY’S AFFILIATES FOR ANY DAMAGES
ARISING FROM CLAIMS BROUGHT BY [ * ]. IT IS UNDERSTOOD THAT THE FOREGOING SENTENCES SHALL NEITHER
(A) LIMIT THE OBLIGATIONS OF BAYER, ON THE ONE HAND, OR ONYX, ON THE OTHER HAND, TO INDEMNIFY THE
OTHER FROM AND AGAINST THIRD PARTY CLAIMS UNDER THIS ARTICLE XII, NOR (B) AFFECT EITHER PARTY’S
RIGHTS AND OBLIGATIONS UNDER SECTIONS 4.1(b) AND 5.1(b) OF THIS AGREEMENT.

     Section 12.7 Disclaimer of Warranties. Except as expressly set forth in Article XIII of this
Agreement, no party has made, and nothing in this Agreement shall be construed as, a warranty or
representation (a) that any Co-Promotion Collaboration Products imported, sold, offered for sale,
manufactured or otherwise disposed of under this Agreement are or will be free from infringement of
patents, copyrights, trademarks, industrial design or other intellectual property rights of any
Third Party, or (b) regarding the effectiveness, value, prospects for success (whether financial,
regulatory or otherwise), safety, non-toxicity, or patentability of the Co-Promotion Collaboration
Products or related technology or any information or results provided by any party pursuant to this
Agreement. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT OR IN THE COLLABORATION AGREEMENT, EACH
PARTY EXPRESSLY DISCLAIMS, WAIVES, RELEASES, AND RENOUNCES ANY CAUSE OF ACTION BASED ON ANY
REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED EITHER IN FACT OR BY OPERATION OF LAW,
BY STATUTE OR OTHERWISE, WHETHER WRITTEN OR ORAL, OR ARISING FROM COURSE OF PERFORMANCE, COURSE OF
DEALING OR USAGE OF TRADE, INCLUDING, WITHOUT LIMITATION, ANY REPRESENTATION OR WARRANTY

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

35

 

WITH RESPECT TO ANY FUTURE EVENTS, PROSPECTS OR PROJECTIONS, TO NONINFRINGEMENT, VALUE,
ADEQUACY, FREEDOM FROM FAULT, QUALITY, EFFICIENCY, SUITABILITY, CHARACTERISTICS OR USEFULNESS, OR
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

     Section 12.8 Regulatory Compliance.

          (a) Each of Onyx and Bayer shall reasonably cooperate with the other party in its efforts
toward ensuring that all government price and gift reporting, sales, marketing and promotional
practices in respect of the Co-Promotion Collaboration Product meet the standards required by
Applicable Laws, including without limitation, state and federal laws and regulations, as well as
applicable guidelines concerning the advertising of prescription drug products, the Office of the
Inspector General’s (“OIG”) Compliance Guidance Program, the American Medical Association (the
“AMA”) Guidelines on Gifts to Physicians, the PhRMA Code, and the ACCME Standards.

          (b) In accordance with Section 6.1, each of Onyx and Bayer shall provide its employees and its
contract sales force, if any, involved in sales, marketing, promotion, or price or gift reporting
for the Co-Promotion Collaboration Product appropriate training on proper marketing and sales
techniques. Such training will include, among other topics, FDA requirements and other state and
federal regulations and guidelines concerning the advertising of prescription drug products, the
OIG Compliance Guidance Program, the AMA Guidelines on Gifts to Physicians, the PhRMA Code, and the
ACCME Standards. If requested by the other party, each of Onyx and Bayer shall provide a written
description of the training to the other party no less frequently than on an annual basis.

          (c) Onyx shall provide to Bayer upon request copies of all Onyx documents that are related to
[ * ] and other [ * ] under Applicable Laws. This will include, but is not necessarily limited to,
[ * ], and [ * ].

          (d) Each of Onyx and Bayer shall reasonably cooperate with the other party to provide the
other party access to any and all information, data and reports required by the other in order to
comply with the relevant provisions of the Medicare Modernization Act (“MMA”) and any other
Applicable Laws, including without limitation reporting requirements, in a timely and appropriate
manner. Onyx shall [ * ] with respect to any sales of the Co-Promotion Collaboration Products by
Onyx [ * ] is [ * ] such that [ * ] can [ * ]. Bayer shall [ * ] related to the Co-Promotion
Collaboration Products is [ * ]; provided however, that Bayer shall [ * ].

          (e) Onyx shall [ * ] any data or other information covered by this Section 12.8 [ * ], and
shall advise Bayer if [ * ]. If Onyx has a question about whether a [ * ] needs to be [ * ],
Onyx’s obligation shall be satisfied by [ * ].

          (f) Bayer shall provide to Onyx [ * ] that Bayer proposes [ * ]. Bayer further agrees to seek
confidential treatment of any such information related to Onyx that it submits to any governmental
entity [ * ].

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

36

 

          (g) Onyx and Bayer shall [ * ]. In the event that the parties [ * ] or of the [ * ], then the
parties shall [ * ].

ARTICLE XIII

REPRESENTATIONS, WARRANTIES AND COVENANTS

     Section 13.1 Representations by Onyx. Onyx represents and warrants to Bayer that:

          (a) the execution, delivery and performance of this Agreement by Onyx does not conflict with,
or constitute a breach of or under, any order, judgment, agreement or instrument to which Onyx is a
party;

          (b) the execution, delivery and performance of this Agreement by Onyx does not require the
consent of any Person or the authorization of (by notice or otherwise) any Governmental or
Regulatory Authority;

          (c) there are no actions, suits, proceedings or claims pending against Onyx, any of its
Affiliates or, to the best of Onyx’s knowledge, Third Parties from whom Onyx has obtained any
intellectual property rights covering the Co-Promotion Collaboration Product, or, to the best of
Onyx’s knowledge, threatened against Onyx, any of its Affiliates or any Third Party from whom Onyx
has obtained any intellectual property rights covering the Co-Promotion Collaboration Product, at
law or equity, or before or by any court or by any Governmental or Regulatory Authority relating to
the Co-Promotion Collaboration Product, or any matter contemplated herein;

          (d) Onyx holds all right, title and interest to the Onyx Trademarks (as defined in the
Collaboration Agreement) and such trademarks are in full force and from the Co-Promotion Effective
Date Onyx will use its Commercially Reasonable Efforts to maintain such trademarks;

          (e) all of its employees who are involved in the contracting for, or marketing, selling or
reporting the price of Co-Promotion Collaboration Products that are reimbursed by Medicare,
Medicaid and all other federal healthcare programs (as defined in 42 U.S.C. Section 1320(a)7(b)(f))
have received appropriate training (or will, prior to deployment, receive appropriate training) on
proper marketing and sales techniques consistent with the obligations of Bayer pursuant to the CIA
and as directed by the Executive Committee; and

          (f) it has not and has never been, nor have any of its employees, agents or subcontractors who
may provide services under this Agreement ever been debarred or, to the best of its knowledge, (i)
convicted of a crime for which a person or entity can be debarred under Section 306(a) or 306(b) of
the United States Generic Drug Enforcement Act of 1992 or under 42 U.S.C. Sections 1320-7; or (ii)
sanctioned by, or suspended, excluded or otherwise ineligible to participate in any federal health
care program, including Medicare and Medicaid or in Federal Procurement or non-procurement
programs.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

37

 

     Section 13.2 Representations by Bayer. Bayer represents and warrants to Onyx that:

          (a) the execution, delivery and performance of this Agreement by Bayer does not conflict with,
or constitute a breach of or under, any order, judgment, agreement or instrument to which Bayer is
a party;

          (b) the execution, delivery and performance of this Agreement by Bayer does not require the
consent of any Person or the authorization of (by notice or otherwise) any Governmental or
Regulatory Authority;

          (c) there are no actions, suits, proceedings or claims pending against Bayer, any of its
Affiliates or, to the best of Bayer’s knowledge, Third Parties from whom Bayer has obtained any
intellectual property rights covering the Co-Promotion Collaboration Product, or, to the best of
Bayer’s knowledge, threatened against Bayer, any of its Affiliates or any Third Party from whom
Bayer has obtained any intellectual property rights covering the Co-Promotion Collaboration
Product, at law or equity, or before or by any court or by any Governmental or Regulatory Authority
relating to the Co-Promotion Collaboration Product, or any matter contemplated herein;

          (d) Bayer and its Affiliates or, to the best of Bayer’s knowledge, Third Parties from whom
Bayer has obtained any intellectual property rights covering the Co-Promotion Collaboration
Product, have all the rights in all intellectual property covering the Co-Promotion Collaboration
Product required to enable Bayer to make, use, sell and offer to sell the Co-Promotion
Collaboration Product and to grant to Onyx the rights granted herein;

          (e) Bayer holds all right, title and interest to the Bayer Trademarks (as defined in the
Collaboration Agreement) and Product Trademark, and such trademarks are in full force and from the
Co-Promotion Effective Date Bayer will use its Commercially Reasonable Efforts to maintain such
trademarks; and

          (f) the Co-Promotion Collaboration Product to be distributed by Bayer will, at the time of
shipment by or on behalf of Bayer, not be misbranded or adulterated under the terms of the Act or
comparable state laws.

          (g) all of its employees who are involved in the contracting for, or marketing, selling or
reporting the price of Co-Promotion Collaboration Products that are reimbursed by Medicare,
Medicaid and all other federal healthcare programs (as defined in 42 U.S.C. Section 1320(a)7(b)(f))
have received appropriate training (or will, prior to deployment, receive appropriate training) on
proper marketing and sales techniques consistent with its obligations pursuant to the CIA; and

          (h) it has not and has never been, nor have any of its employees, agents or subcontractors who
may provide services under this Agreement ever been debarred or, to the best of its knowledge, (i)
convicted of a crime for which a person or entity can be debarred under Section 306(a) or 306(b) of
the United States Generic Drug Enforcement Act of 1992 or under 42 U.S.C. Sections 1320-7; or (ii)
sanctioned by, or suspended, excluded or otherwise ineligible

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

38

 

to participate in any federal health care program, including Medicare and Medicaid or in
Federal Procurement or non-procurement programs.

ARTICLE XIV

NOTICES

     Except as otherwise specifically provided herein, any notice or other document to be given
under this Agreement shall be in writing and shall be deemed to have been duly given if sent by
nationally recognized overnight courier or confirmed facsimile transmission to a party (followed by
hard copy by mail) or delivered in person to a party at the address or facsimile number set out
below for such party or such other address as the party may from time to time designate by written
notice to the other in accordance with this Article XIV:

If to Bayer:

Bayer Pharmaceuticals Corporation

400 Morgan Lane

West Haven, CT 06516

Attention: Senior Vice President, Global Licensing

Telephone: (203) 812-2000

Facsimile: (203) 812-6311

With a copy to:

Bayer Pharmaceuticals Corporation

400 Morgan Lane

West Haven, CT 06516

Attention: Vice President and General Counsel

Telephone: (203) 812-6081

Facsimile: (203) 812-2795

If to Onyx:

Onyx Pharmaceuticals, Inc.

2100 Powell Street

Emeryville, CA 94608

Attention: Chief Executive Officer

Telephone: (510) 597-6500

Facsimile: (510) 597-6600

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

39

 

With a copy to:

Cooley Godward LLP

Five Palo Alto Square

3000 El Camino Real

Palo Alto, CA 94306

Attention: Robert L. Jones, Esq.

Telephone: (650) 843-5034

Facsimile: (650) 849-7400

Any such notice or other document shall be deemed to have been received by the addressee
simultaneously with the transmission or delivery thereof.

ARTICLE XV

DISPUTE RESOLUTION

     The parties recognize that disputes under this Agreement may arise from time to time arise
(other than matters for which decisions or approvals are reserved to Bayer under this Agreement)
(“Dispute(s)”). It is the objective of the parties to establish procedures to facilitate the
resolution of Disputes in an expedient manner by mutual cooperation and without resort to
litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in
Article 25 of the Collaboration Agreement if and when a Dispute arises under this Agreement.

ARTICLE XVI

MISCELLANEOUS PROVISIONS

     Section 16.1 Assignment. The parties agree that the assignment of this Agreement shall be
covered by Section 28.1 of the Collaboration Agreement. Additionally, except upon the prior
written consent of the other party, this Agreement shall not be assigned to any person or entity
other than a permitted assignee of the Collaboration Agreement in conjunction with an assignment of
the Collaboration Agreement.

     Section 16.2 Governing Law. This Agreement shall be governed by and interpreted in accordance
with the substantive and internal laws of the State of California without regard to its or any
other jurisdiction’s choice of law rules. Any disputes under this Agreement shall be brought in
the state or federal courts located in California. The parties irrevocably accept the exclusive
jurisdiction of such courts solely and specifically for the purpose of adjudicating disputes
arising out of or in connection with this Agreement and any other agreement entered into pursuant
hereto or in connection herewith, and in no event shall any party be deemed to have consented to
such jurisdiction for any other purpose. Each party further agrees that such courts provide a
convenient forum for any such action, and waives any objections or challenges to venue with respect
to such courts.

     Section 16.3 Waiver. Except as specifically provided for herein, the waiver from time to time
by either of the parties of any of their rights or their failure to exercise any remedy shall

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

40

 

not operate or be construed as a continuing waiver of same or of any other of such party’s
rights or remedies provided in this Agreement.

     Section 16.4 Entire Agreement. This Agreement and any and all documents or agreements
referenced herein contain all of the terms agreed to by the parties regarding the subject matter of
this Agreement and shall supersede any prior oral or written agreements, understandings or
arrangements between them as to the subject matter hereof; provided, however, that
(except as specified in the following sentence) the Collaboration Agreement shall remain an
independent agreement between the parties and continue to govern the parties’ development and
collaboration activities pursuant to the terms thereof unless specifically modified by the terms of
this Agreement. The parties hereby expressly agree that this Agreement shall supersede any and all
provisions of the Collaboration Agreement concerning any Co-Promotion activities in the United
States involving the Co-Promotion Collaboration Product, including without limitation Section 13.6
(Co-Promotion Program), Section 13.7 (Co-Promotion Sales Efforts), Section 13.8 (Co-Promotion
Costs), Section 13.9 (Training Program), Section 13.10 (Advertising and Promotional Materials),
Section 13.12 (Price Setting in the United States, but only the first sentence contained in such
section), Article 14 (Sales Responsibility) and Article 27 (Products Liability and
Indemnification). This Agreement refers to the following provisions of the Collaboration Agreement
which are not superseded and which will continue in full force and effect: Section 13.12 (Price
Setting in the United States, only the last sentence contained in such section), Section 16.1 (as
it relates to activities outside the United States), Section 17.2 (Records), Article 18
(Trademarks), Article 19 (Manufacturing and Supply), Article 22 (Confidentiality), Article 23
(Federal State Tax Characterization) with the exception that the amortization periods referenced in
Sections 23.5(iv) and 23.5(v) shall read 180 months instead of 60 months, Article 25 (Dispute
Resolution), Section 28.1 (Assignment) and Section 28.9 (Severability). This Agreement may not be
amended, modified, altered or supplemented except by means of a written agreement or other
instrument executed by both of the parties hereto. No course of conduct or dealing between the
parties shall act as a modification or waiver of any provisions of this Agreement.

     Section 16.5 Severability. If any term, covenant or condition of this Agreement or the
application thereof to any party or circumstance shall, to any extent, be held to be invalid or
unenforceable, then the parties agree to be bound by the provisions of Section 28.9 of the
Collaboration Agreement.

     Section 16.6 Relationship of the Parties. The parties hereto are acting and performing as
independent contractors, and nothing in this Agreement creates the relationship of partnership,
joint venture, sales agency or principal and agent, except as set forth in Article 23 of the
Collaboration Agreement. Neither party is the agent of the other, and neither party may hold
itself out as such to any other Person. All financial obligations associated with each party’s
business shall be the sole responsibility of such party.

     Section 16.7 No Implied Licenses. Each of the parties hereby acknowledges and agrees that,
except as otherwise explicitly provided in this Agreement, such party shall not by

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

41

 

entering into this Agreement have, assert or acquire any right, title or interest in or to any
intellectual property or other proprietary rights of the other party.

     Section 16.8 Public Announcements. During the Term, each party (the “Publishing Party”) shall
submit to the other party (the “Non-Publishing Party”) for review and approval all proposed press
releases, public filings with the SEC, academic, scientific and medical publications and public
presentations relating to the Co-Promotion Collaboration Product or the terms of this Agreement.
Such review and approval shall be conducted for the purposes of preserving intellectual property
protection and the confidentiality of trade secrets and business terms contained in this Agreement
and determining whether any portion of the proposed publication or presentation containing the
Confidential Information of the Non-Publishing Party should be modified or deleted, and (in the
case of a disclosure that Onyx wishes to make) to determine whether such disclosure is in the best
interests of the parties in connection with the promotion of the Co-Promotion Collaboration Product
(such determination to be made in Bayer’s reasonable discretion). Written copies of such proposed
publications and presentations (other than press releases or SEC filings) shall be submitted to the
Non-Publishing Party no later than [ * ] days before submission for publication or presentation.
Subject to Applicable Laws, written copies of proposed press releases and SEC filings containing
information regarding the Co-Promotion Collaboration Product or this Agreement shall be submitted
to the Non-Publishing Party no later than [ * ] before release or filing. In the event that either
party is required to file a Form 8-K describing this Agreement and the transactions contemplated
hereby, written copies of the Form 8-K shall be submitted to the Non-Publishing Party no later than
[ * ] before filing, together with a form of the Agreement intended to be filed and a copy of the
confidential treatment request to be submitted with such filing. The Publishing Party shall seek
confidential treatment of Confidential Information which may be contained in the Agreement, as
shall be mutually determined between the parties, and shall use its best efforts to obtain
confidential treatment thereof. The Publishing Party shall promptly notify the Non-Publishing
Party of any determination made by the SEC with respect to such confidential treatment request.
The Non-Publishing Party shall provide its comments, if any, and (if it so chooses) its approval
within (a) [ * ], in the case of a press release or SEC filings, and (b) [ * ] of its receipt of
any other written copy. With respect to matters other than press releases or SEC filings, the
review period may be extended for an additional [ * ] days in the event the Non-Publishing Party
can demonstrate reasonable need for such extension. This period may be further extended by mutual
written agreement of the parties. Onyx and Bayer will each comply with standard academic practice
regarding authorship of scientific publications and recognition of contribution of other parties in
any publications.

     Section 16.9 Counterparts. This Agreement shall become binding when any one or more
counterparts hereof, individually or taken together, shall bear the signatures of each of the
parties hereto. This Agreement may be executed in any number of counterparts, each of which shall
be deemed an original as against the party whose signature appears thereon, but all of which taken
together shall constitute but one and the same instrument.

     Section 16.10 Force Majeure. Neither party shall be liable or responsible to the other party
for loss or damages, nor shall it have any right to terminate this Agreement for any default

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

42

 

or delay attributable to any event beyond its reasonable control and without its fault or
negligence, including but not limited to acts of God, acts of government (including injunctions),
fire, flood, earthquake, strike, lockout, labor dispute, breakdown of plant, shortage of critical
equipment, loss or unavailability of manufacturing facilities or material, casualty or accident,
civil commotion, acts of public enemies, acts or terrorism or threat of terrorist acts, blockage or
embargo and the like (a “Force Majeure Event”); provided, however, that in each
such case the party affected shall use Commercially Reasonable Efforts to avoid such occurrence and
to remedy it promptly. The party affected shall give prompt notice of any such cause to the other
party. The party giving such notice shall thereupon be excused from such of its obligations
hereunder as it is thereby disabled from performing for so long as it is so disabled and the party
receiving notice shall be similarly excused from its respective obligations which it is thereby
disabled from performing; provided, however, that such affected party commences and
continues to take reasonable and diligent actions to cure such cause.

     Section 16.11 Interpretation. The parties hereto acknowledge and agree that: (a) each party
and its representatives have reviewed and negotiated the terms and provisions of this Agreement and
have contributed to its preparation; and (b) the terms and provisions of this Agreement shall be
construed fairly as to each party hereto and not in favor of or against either party, regardless of
which party was generally responsible for the preparation or drafting of this Agreement.

     Section 16.12 Certain Expenses and Commissions. Except as otherwise expressly set forth in
this Agreement, the parties hereto shall each pay all their costs and expenses, including
reasonable attorneys’ fees, court costs and accounting fees, incurred in connection with the
preparation, negotiation, execution and delivery of this Agreement, respective brokerage fees,
commissions and finder’s fees, if any, and shall indemnify and hold the other harmless from and
against any and all other claims or liabilities for such costs and expenses, brokerage fees,
commissions and finder’s fees incurred by reason of any action taken by any such broker, commission
agent or finder.

     Section 16.13 Headings. The headings contained in this Agreement are for reference purposes
only and shall not affect in any way the meaning or interpretation of this Agreement.

     Section 16.14 Days. Except as expressly stated otherwise, all references to “days” in this
Agreement shall mean calendar days.

     IN WITNESS WHEREOF, the parties have duly executed this U.S. Co-Promotion Agreement.

	 	 	 	 	 	 	 
	BAYER PHARMACEUTICALS

CORPORATION

	 	ONYX PHARMACEUTICALS, INC.

	 
	By:

	 	/s/ Paolo Pucci
	 	By:
	 	/s/ Hollings C. Renton
	 

	 	Paolo Puccci
	 	 	 	Hollings C. Renton

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

43

 

	 	 	 	 	 	 	 
	 

	 	Sr. VP and President
	 	 	 	Chairman, President, and CEO
	 

	 	Global Specialty Business Unit	 	 	 	 
	 

	 	Bayer Healthcare LLC	 	 	 	 

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

44

 

EXHIBIT A

FORM PROFIT AND LOSS STATEMENT

P&L Statement

	 	 	 	 	 	 	 	 	 
	 

	 	Bayer
	 	Onyx
	 	TOTAL
	 	% Net

Sales

Gross Sales

[ * ]

Co-Promotion Net Sales

[ * ]

[ * ]

US Sublicense Revenue

[ * ]

Gross Profit

     •     [ * ]

[ * ]

[ * ]

Co-Promotion Marketing Profit/Loss excluding R&D and Sales Force Expenses and MSL Expenses

Co-Development Costs (R&D)

Split of Profit/Loss excluding Sales Force Expenses and MSL Expenses

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS
BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

45<PAGE>

                                                                     Exhibit 4.1

            WAIVER AND FIRST AMENDMENT TO TERM LOAN CREDIT AGREEMENT

     This Waiver and First Amendment to Term Credit Loan Agreement (this
"Amendment") is made as of this 10th day of March, 2006 by and among and
Developers Diversified Realty Corporation, a corporation organized under the
laws of the State of Ohio (the "Borrower"), JPMorgan Chase Bank, N.A., successor
by merger to Bank One, N.A., not individually, but as "Administrative Agent",
and the several banks, financial institutions and other entities from time to
time parties to the Loan Agreement referred to below (the "Lenders").

                                    RECITALS

     A. Borrower, Administrative Agent, and the Lenders are parties to a Term
Loan Credit Agreement dated as of May 20, 2004 (the "Loan Agreement"). All
capitalized terms used in this Amendment and not otherwise defined herein shall
have the meanings described as such terms in the Loan Agreement.

     B. Borrower, Administrative Agent and certain lenders are parties to a
Sixth Amended and Restated Credit Agreement dated as of March 30, 2005, as
amended (the "Revolving Credit Agreement").

     C. The parties intended for the covenants in the Loan Agreement to be
consistent with those contained in the Revolving Credit Agreement and
accordingly have agreed to amend the Loan Agreement as provided herein to
reflect the understanding of the parties.

     NOW, THEREFORE, in consideration of the foregoing recitals and for other
good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

                                   AMENDMENTS

     1. The foregoing recitals to this Amendment are incorporated into and made
part of this Amendment.

     2. The following definitions in Article 1 of the Loan Agreement are hereby
amended, restated or added as follows:

          (a) The definition of "Acceptable Jurisdiction" is hereby added to the
Loan Agreement as follows:

     "Acceptable Jurisdiction" means a place (in addition to the United States
and Puerto Rico) where Unencumbered Assets can be located, which shall be
subject to the approval of the Administrative Agent, based on satisfactory
advice received by it from local counsel in such jurisdiction with respect to
the procedure for enforcement of a U.S. judgment in such jurisdiction, and the
collection of such judgment from assets located there.

          (b) The definition of "Acquisition Asset" is hereby restated to read
as follows:

     "Acquisition Asset" means an asset which has not been owned for at least a
period of eighteen months.

<PAGE>

          (c) The definition of "Consolidated Capitalization Value" is hereby
amended by deleting the reference to 0.090 and inserting 0.0825 in lieu thereof.

          (d) The definition of "Equity Value" is hereby amended and restated to
read as follows:

     "Equity Value" means, with respect to a Subsidiary owned and in operation
for a period of two or more consecutive full fiscal quarters after the Agreement
Execution Date, by the Borrower or one of its other Subsidiaries, an amount
equal to (A) the product of (i) the sum of net income (or loss) for the most
recent two consecutive fiscal quarters without giving effect to depreciation and
amortization, gains or losses from extraordinary items, gains or losses on sales
of real estate, and gains or losses on investments in marketable securities for
such period, plus the amount of interest expense for such period on the
aggregate principal amount of the Indebtedness of such Subsidiary, multiplied by
(ii) two, divided by (B) 0.0825, and then minus (C) Indebtedness of the
Subsidiary as of the date of determination. For any Subsidiary not owned and in
operation for two fiscal quarters, until it or its Properties have been owned
and operated by the Borrower or one of its other Subsidiaries for two or more
consecutive full fiscal quarters, "Equity Value" shall mean the Borrower's
estimated annual Net Operating Income for the Projects owned by such Subsidiary
based on leases in existence at the date such Subsidiary is formed or purchased
divided by 0.0825, and then minus the Indebtedness of such Subsidiary as of the
date of determination.

          (e) The definition of "Excluded Subsidiary" is hereby added to the
Loan Agreement as follows:

     "Excluded Subsidiary" means Sun Center Limited, so long as such Subsidiary
is owned in part by unaffiliated third parties whose consent would be required
for such Subsidiary to become a Subsidiary Guarantor, and no Project owned by
such Excluded Subsidiary is included as an Unencumbered Asset.

          (f) The definition of "Portfolio Acquisition" is hereby added to the
Loan Agreement as follows:

     "Portfolio Acquisition" means an acquisition by Borrower and/or a
Subsidiary of Projects with an aggregate purchase price in excess of
$250,000,000 in a single transaction or series of related transactions.

          (g) The definition of "Restricted Payment" is hereby added to the Loan
Agreement and to read as follows:

     "Restricted Payment" means any dividend or other distribution (whether in
cash, securities or other property) with respect to any Capital Stock in the
Borrower or any Subsidiary, or any payment (whether in cash, securities or other
property), including any sinking fund or similar deposit, on account of the
purchase, redemption, retirement, acquisition, cancellation or termination of
any such Capital Stock in the Borrower or any option, warrant or other right to
acquire any such Capital Stock in the Borrower, or any transaction that has a
substantially similar effect.

                                       -2-

<PAGE>

          (h) The definition of "Unencumbered Asset" is hereby restated as
follows:

     "Unencumbered Asset" means, any Project located in the United States,
Puerto Rico or an Acceptable Jurisdiction 100% of which is owned in fee simple
or ground leased by the Borrower or a Subsidiary Guarantor (provided that a
Project which is ground leased shall be included as an Unencumbered Asset only
if such ground lease is a Financeable Ground Lease) which, as of any date of
determination, (a) is not subject to any Liens or claims (including restrictions
on transferability or assignability) of any kind (including any such Lien, claim
or restriction imposed by the organizational documents of any Subsidiary
Guarantor) other than (i) Permitted Liens set forth in Sections 6.16(i) through
6.16(iv)), and (ii) restrictions on transferability in the case of a Qualifying
Jointly-Owned Subsidiary, (b) is not subject to any agreement (including (i) any
agreement governing Indebtedness and (ii) if applicable, the organizational
documents of any Subsidiary Guarantor) which prohibits or limits the ability of
the Borrower or any Subsidiary Guarantor to create, incur, assume or suffer to
exist any Lien upon any assets or Capital Stock of the Borrower or any
Subsidiary Guarantor, including, without limitation, any negative pledge or
similar covenant or restriction, except as permitted under Section 19 of the
Subsidiary Guaranty, (c) is not subject to any agreement (including any
agreement governing Indebtedness incurred in order to finance or refinance the
acquisition of such asset) which entitles any Person to the benefit of any Lien
(other than Permitted Liens set forth in Sections 6.16(i) through 6.16(iv)) on
any assets or Capital Stock of the Borrower or any Subsidiary Guarantor, except
as permitted under Section 19 of the Subsidiary Guaranty, or would entitle any
Person to the benefit of any Lien (other than Permitted Liens set forth in
Sections 6.16(i) through 6.16(iv)) on such assets or Capital Stock upon the
occurrence of any contingency (including, without limitation, pursuant to an
"equal and ratable" clause), and (d) either has been improved with an
income-producing building or buildings which are substantially completed and
occupied or is a Pre-Leased Project Under Construction.

          (i) The definition of "Value of Unencumbered Assets" is hereby
restated as follows:

     "Value of Unencumbered Assets" means, as of any date, the sum of (A) the
amount determined by dividing the Net Operating Income for each Project which is
an Unencumbered Asset (excluding the Net Operating Income for any Acquisition
Asset which is an Unencumbered Asset) as of such date for a calculation period
which shall be either the immediately preceding two (2) full fiscal quarters or,
if so requested by Borrower or the Administrative Agent, the one (1) immediately
preceding full fiscal quarter and the then current partial quarter (in all cases
as annualized) by 0.0825 (provided that not more than 15% of the Value of
Unencumbered Assets with respect to Projects shall be attributable to
Unencumbered Assets which are ground leased and not more than 15% of the Value
of Unencumbered Assets shall be attributable to Unencumbered Assets not located
in the United States or Puerto Rico) plus (B) for each Pre-Leased Project Under
Construction, 100% of the then-current book value, as determined in accordance
with GAAP, of such Pre-Leased Project Under Construction, provided that the
aggregate amount added to value under this clause (B) shall not exceed ten
percent (10%) of the total Value of Unencumbered Assets, plus (C) cash from
like-kind exchanges on deposit with a qualified intermediary (provided that not
more than 5% of the Value of Unencumbered Assets shall be attributable to the
proceeds of this clause). If a Project is no longer owned as of the date of
determination, then no value shall be included from such Project, except for
purposes of such financial covenant comparing the Net Operating Income from

                                       -3-

<PAGE>

Unencumbered Assets to Consolidated Interest Expense under this Agreement.
Notwithstanding the foregoing and with respect to any Acquisition Asset which is
an Unencumbered Asset, each such Acquisition Asset shall be valued at the lower
of its acquisition cost or market value, as determined in accordance with GAAP.

     3. Sub-sections 6.1(i), (ii) and (iii) of the Loan Agreement are hereby
restated as follows, sub-section 6.1(iv) is hereby deleted in its entirety and
the other sub sections of Section 6.1 are renumbered appropriately:

     (i) As soon as available, but in any event not later than 45 days after the
close of each fiscal quarter, for the Borrower and its Subsidiaries, a copy of
Borrower's Financial Statements in the form filed under 10-Q which shall include
an unaudited consolidated balance sheet as of the close of each such period and
the related unaudited consolidated statements of income and retained earnings
and of cash flows of the Borrower and its Subsidiaries for such period and the
portion of the fiscal year through the end of such period, setting forth in each
case in comparative form the figures for the previous year, all certified by the
Borrower's chief financial officer or chief accounting officer;

     (ii) As soon as available, but in any event not later than 45 days after
the close of each fiscal quarter, for the Borrower and its Subsidiaries, a copy
of the Borrower's Quarterly Financial Supplement and other schedules as may be
required containing the following reports in form and substance reasonably
satisfactory to the Lenders, all certified by the entity's chief financial
officer or chief accounting officer: a statement of Funds From Operations, a
statement detailing Consolidated Outstanding Indebtedness, Consolidated Secured
Indebtedness, Consolidated Unsecured Indebtedness, Consolidated Cash Flow and an
Asset Schedule listing all assets and their net operating income with a
breakdown between Unencumbered Assets and other assets, and newly acquired
Projects, Borrower will provide such other information as may be reasonably
requested;

     (iii) As soon as available, but in any event not later than 90 days after
the close of each fiscal year, for the Borrower and its Subsidiaries, audited
financial statements in the form filed as 10-K, including a consolidated balance
sheet as at the end of such year and the related consolidated statements of
income and retained earnings and of cash flows for such year, setting forth in
each case in comparative form the figures for the previous year, without a
"going concern" or like qualification or exception, or qualification arising out
of the scope of the audit, prepared by PricewaterhouseCoopers (or other
independent certified public accountants of nationally recognized standing
reasonably acceptable to Administrative Agent);

     4. Section 6.11 of the Loan Agreement is hereby restated as follows:

     6.11 Restricted Payments Except as otherwise set forth in this Agreement,
the Borrower will not, and will not permit any of its Subsidiaries to, declare
or make, or agree to pay or make, directly or indirectly, any Restricted
Payment, except (a) the Borrower may declare and pay dividends with respect to
its Capital Stock payable solely in additional shares of its common stock, (b)
Subsidiaries may declare and pay dividends ratably with respect to their Capital
Stock, (c) the Borrower may make Restricted Payments pursuant to and in
accordance with stock option plans or other benefit plans for management or
employees of the Borrower and its Subsidiaries, and (d) the Borrower may make
Restricted Payments if there is no then existing Default or

                                       -4-

<PAGE>

Unmatured Default hereunder (after notice thereof to Borrower) and either (i)
Restricted Payments paid on account of any fiscal quarter, in the aggregate,
would not exceed 95% of Funds From Operations for such fiscal quarter, or (ii)
Restricted Payments paid on account of any fiscal year, in the aggregate, would
not exceed 90% of Funds From Operations for such fiscal year. Notwithstanding
the foregoing, the Borrower shall be permitted at all times to distribute
whatever amount of dividends is necessary to maintain its tax status as a real
estate investment trust.

     5. Section 6.13 of the Loan Agreement is hereby restated as follows:

     6.13 Delivery of Subsidiary Guaranties. All Subsidiaries of the Borrower
which own a Project except for Excluded Subsidiaries and except for a Subsidiary
which owns a Project encumbered by first mortgage financing which is prohibited
from issuing guaranties by either the terms of the first mortgage loan documents
or the terms of other financing secured by a pledge of the direct or indirect
interest in the Capital Stock in such Subsidiary shall be required to be a
Subsidiary Guarantor. Borrower shall cause each of its existing Subsidiaries
which are required to be Subsidiary Guarantors to execute and deliver to the
Agent the Subsidiary Guaranty. At Borrower's election, additional Subsidiaries
may execute the Subsidiary Guaranty but notwithstanding the foregoing, those
Subsidiaries that have executed the Subsidiary Guaranty but that are not
obligated to be a Subsidiary Guarantor pursuant to the terms of this Section
6.13 shall not be bound by the terms of the Subsidiary Guaranty and shall have
no liability thereunder. Upon request from Borrower, and delivery of
satisfactory evidence that a particular Subsidiary is not required to be a
Subsidiary Guarantor, Administrative Agent shall acknowledge in writing that
such Subsidiary is not a Subsidiary Guarantor even though it may have executed
the Subsidiary Guaranty. From and after the date hereof, any Subsidiary (whether
or not currently existing) which is required to be a Subsidiary Guarantor will
automatically be deemed to be a Subsidiary Guarantor without any further action
on its part. To confirm that it has become a Subsidiary Guarantor, Borrower
agrees that not less than once every twelve months and within thirty (30) days
following the closing of a Portfolio Acquisition (or final closing if the
closing occurs in phases) it will cause each such Subsidiary to execute a
Joinder to the Subsidiary Guaranty in the form attached as Exhibit A to the
Subsidiary Guaranty if it has not already executed the Subsidiary Guaranty or a
Joinder, however the failure to execute such Joinder shall not impair the
obligations of such Subsidiary under the Subsidiary Guaranty. Upon request of
Administrative Agent Borrower shall deliver to Administrative Agent a list of
all Projects and which entity owns such Project. Notwithstanding the foregoing,
in no event shall any asset owned by a Subsidiary be included as an Unencumbered
Asset unless such Subsidiary has executed the Subsidiary Guaranty or a Joinder
thereto.

     6. Section 6.20 of the Loan Agreement is hereby restated as follows:

     6.20 Consolidated Net Worth. The Borrower shall maintain a Consolidated Net
Worth of not less than the sum of (i) $2,500,000,000.00 plus (ii) seventy-five
percent (75%) of the aggregate proceeds received by the Borrower (net of
customary related fees and expenses) in connection with any offering of stock,
including, without limitation, perpetual preferred stock and all other preferred
stock, in the Borrower after December 31, 2004 and on or prior to the date such
determination of Consolidated Net Worth is made provided that no proceeds shall
be deemed received to the extent that such offering involves only the
replacement or reissuance of common or preferred stock.

                                       -5-

<PAGE>

     7. Section 6.21(iii) is hereby deleted from the Loan Agreement and the
other sub-sections renumbered appropriately.

     8. Section 6.22(d) is hereby by amended to (a) delete the clause "which
investigation shall at a minimum comply with the specifications and procedures
attached hereto as Exhibit G" and insert in lieu thereof the clause "consistent
with standards used by institutional purchasers of similar properties" and (b)
delete the clause "and to assure compliance with the specifications and
procedures."

     9. Sections 6.23(f) and (g) are hereby restated as follows:

     (f) The Consolidated Group's aggregate Investment in Properties not located
in the United States or Puerto Rico shall not at any time exceed twenty-five
percent (25%) of Consolidated Capitalization Value.

     (g) The Consolidated Group's aggregate Investment in Developable Land,
Passive Non-Real Estate Investments, First Mortgage Receivables, Assets Under
Development, and Properties not located in the United States or Puerto Rico
shall not at any time exceed thirty percent (30%) of Consolidated Capitalization
Value.

     10. Section 7.6 is hereby amended to delete the references to "$10,000,000"
and insert in lieu thereof of "$25,000,000" and to delete the references to
"$40,000,000" and insert in lieu thereof "$50,000,000."

     11. Section 7.7 of the Loan Agreement is hereby amended to delete the
reference to "$10,000,000" and insert in lieu thereof "$20,000,000."

     12. Section 7.8 is hereby amended to delete the reference to "$10,000,000"
and insert in lieu thereof "$20,000,000."

     13. Section 7.9 is hereby amended to delete the reference to "$10,000,000"
and insert in lieu thereof "$20,000,000."

     14. Exhibit F of the Loan Agreement, the form of Subsidiary Guaranty, is
hereby amended and restated in its entirety by the attached Exhibit F. Borrower
shall cause the Subsidiary Guarantors to execute and deliver such Subsidiary
Guaranty as a requirement for the effectiveness of this Amendment.

     15. Exhibit G of the Loan Agreement is hereby deleted in its entirety.

     16. As of the Effective Date (as defined in Section 21), the Lenders hereby
waive violation, if any, of the covenants of the Loan Agreement that are amended
herein for periods prior to the Effective Date to the extent that Borrower would
have been in compliance with all of such covenants during such periods had the
amendments contained herein been in effect. The waivers granted herein are
limited to the express circumstances described herein and shall not be construed
to constitute (i) a waiver of any other event, circumstance or condition or of
any other right or remedy available to the Administrative Agent or any Lender
pursuant to the Loan Agreement, or (ii) a consent to any departure by the
Borrower or any Subsidiary from any other term or requirement under the Loan
Agreement.

                                       -6-

<PAGE>

     17. The parties hereto intend for the covenants contained in the Loan
Agreement to be consistent with the covenants contained in the Revolving Credit
Agreement, as such agreement may be amended or restated from time to time.
Accordingly, the parties agree that if the Revolving Credit Agreement is amended
or restated to modify covenants that are also contained in the Loan Agreement,
then the covenants in the Loan Agreement shall be amended automatically to
conform to such revised covenants. If the Revolving Credit Agreement is
terminated and replaced by a new revolving credit facility and if each of the
Lenders is a lender under such new revolving credit facility, then the covenants
contained herein shall be deemed to be modified to conform to the covenants
contained in such new revolving credit facility. Otherwise, the covenants
contained in the Loan Agreement at the time of the termination of the Revolving
Credit Agreement shall remain in effect unless the Loan Agreement is amended
pursuant to the procedures set forth therein.

     18. Borrower hereby represents and warrants that:

          (a)  no Default or Unmatured Default exists under the Loan Documents,
               as amended;

          (b)  the Loan Documents are in full force and effect and Borrower has
               no defenses or offsets to, or claims or counterclaims relating
               to, its obligations under the Loan Documents;

          (c)  there has been no material adverse change in the financial
               condition of Borrower as shown in its December 31, 2005 financial
               statements;

          (d)  Borrower has full corporate power and authority to execute this
               Amendment and no consents are required for such execution other
               than any consents which have already been obtained; and

          (e)  all representations and warranties contained in Article 5 of the
               Loan Agreement are true and correct as of the date hereof and all
               references therein to "the date of this Agreement" shall refer to
               "the date of this Amendment."

     19. Except as specifically modified hereby, the Loan Agreement is and
remains unmodified and in full force and effect and is hereby ratified and
confirmed. All references in the Loan Documents to the "Loan Agreement" or the
"Subsidiary Guaranty" henceforth shall be deemed to refer to the Loan Agreement
and the Subsidiary Guaranty as amended by this Amendment.

     20. This Amendment may be executed in any number of counterparts, all of
which taken together shall constitute one agreement, and any of the parties
hereto may execute this Amendment by signing any such counterpart. This
Amendment shall be construed in accordance with the internal laws (and not the
law of conflicts) of the State of Illinois, but giving effect to federal laws
applicable to national banks.

                                       -7-

<PAGE>

     21. This Amendment shall become effective (the "Effective Date") when (i)
it has been executed by Borrower, Administrative Agent, and the Required
Lenders; and (ii) Borrower has delivered a fully executed Subsidiary Guaranty in
the form attached hereto.

     22. Once Administrative Agent receives a fully executed Subsidiary Guaranty
in the form attached hereto, it will return to Borrower the Subsidiary Guaranty
that Administrative Agent received in connection with the Loan Agreement on the
Agreement Execution Date.

                                       -8-

<PAGE>

          IN WITNESS WHEREOF, the Borrower, the Required Lenders and the
Administrative Agent have executed this Amendment as of the date first above
written.

                                        DEVELOPERS DIVERSIFIED REALTY
                                        CORPORATION

                                        By: /s/ WILLIAM H. SCHAFER
                                            ---------------------------------
                                        Print Name: WILLIAM H. SCHAFER
                                        Title: EXECUTIVE VICE PRESIDENT & CFO

                                       S-1

<PAGE>

                                        JPMORGAN CHASE BANK, N.A.,
                                        Individually and as Administrative Agent

                                        By: /s/ KIMBERLY L. TURNER
                                            ------------------------------------
                                        Print Name: KIMBERLY L. TURNER
                                        Title: VICE PRESIDENT

                                       S-2

<PAGE>

                                        WELLS FARGO BANK, N.A.,
                                        Real Estate Finance Group,
                                        Individually and as Syndication Agent

                                        By: /s/ SCOTT S. SOLIS
                                            ------------------------------------
                                        Print Name: SCOTT S. SOLIS
                                        Title: VICE PRESIDENT

                                       S-3

<PAGE>

                                        WACHOVIA BANK, NA,
                                        Individually and as Documentation Agent

                                        By: /s/ RANDY MATTHEWS
                                            ------------------------------------
                                        Print Name: RANDY MATTHEWS
                                        Title: DIRECTOR

                                       S-4

<PAGE>

                                        EUROHYPO AG, NEW YORK BRANCH,

                                        By: /s/ DAVID SARNER
                                            ------------------------------------
                                        Print Name: DAVID SARNER
                                        Title: DIRECTOR

                                        By: /s/ ALICE HA
                                            ------------------------------------
                                        Print Name: ALICE HA
                                        Title: ASSOCIATE

                                       S-5

<PAGE>

                                        SUNTRUST BANK

                                        By: /s/ NANCY B. RICHARDS
                                            ------------------------------------
                                        Print Name: NANCY B. RICHARDS
                                        Title: SENIOR VICE PRESIDENT

                                       S-6

<PAGE>

                                        ALLIED IRISH BANKS, P.L.C.
                                        New York Branch

                                        By:
                                            ------------------------------------
                                        Print Name:
                                                    ----------------------------
                                        Title:
                                               ---------------------------------

                                        By:
                                            ------------------------------------
                                        Print Name:
                                                    ----------------------------
                                        Title:
                                               ---------------------------------

                                       S-7

<PAGE>

                                        LASALLE BANK NATIONAL ASSOCIATION

                                        By: /s/ ROBERT E. GOECKEL
                                            ------------------------------------
                                        Print Name: ROBERT E. GOECKEL
                                        Title: VICE PRESIDENT

                                       S-8

<PAGE>

                                        PNC BANK, NATIONAL ASSOCIATION

                                        By: /s/ MICHAEL E. SMITH
                                            ------------------------------------
                                        Print Name: MICHAEL E. SMITH
                                        Title: SENIOR VICE PRESIDENT

                                       S-9

<PAGE>

                                        CITIZENS BANK OF RHODE ISLAND

                                        By: /s/ CRAIG E. SCHERMERHORN
                                            ------------------------------------
                                        Print Name: Craig E. Schermerhorn
                                        Title: VICE PRESIDENT

                                      S-10

<PAGE>

                                    EXHIBIT F

                               SUBSIDIARY GUARANTY

     This Guaranty is made as of _________, 2006 by the parties identified in
the signature pages thereto, and any Joinder to Guaranty hereafter delivered,
together with any additional Subsidiaries that are deemed to be parties to this
Subsidiary Guaranty pursuant to Section 6.13 of the Loan Agreement described
below (collectively, the "Subsidiary Guarantors"), to and for the benefit of
JPMorgan Chase Bank, N.A., individually ("JPMorgan Chase Bank") and as
administrative agent ("Administrative Agent") for itself and the lenders under
the Loan Agreement (as defined below) and their respective successors and
assigns (collectively, the "Lenders").

                                    RECITALS

     A. The Lenders have made a term loan in the amount of $200,000,000 (the
"Loan") to Developers Diversified Realty Corporation ("Borrower") pursuant to
the terms and conditions set forth in a Term Loan Credit Agreement dated May 20,
2004, as amended between Borrower, JPMorgan Chase Bank, N.A., individually, and
as Administrative Agent, and the Lenders named therein (as amended, modified or
restated from time to time, the "Loan Agreement"). All capitalized terms used
herein and not otherwise defined shall have the meanings ascribed to such terms
in the Loan Agreement.

     B. Borrower has executed and delivered or will execute and deliver to the
Lenders promissory notes as evidence of Borrower's indebtedness to each such
Lender with respect to the Loan (the promissory notes described above from
Borrower, together with any amendments or allonges thereto, or restatements,
replacements or renewals thereof, and/or new promissory notes under the Loan
Agreement, are collectively referred to herein as the "Notes").

     C. Subsidiary Guarantors are subsidiaries of Borrower. Subsidiary
Guarantors acknowledge that the extension of credit by the Administrative Agent
and the Lenders to Borrower pursuant to the Loan Agreement will benefit
Subsidiary Guarantors by making funds available to Subsidiary Guarantors through
Borrower and by enhancing the financial strength of the consolidated group of
which Subsidiary Guarantors and Borrower are members. This Subsidiary Guaranty
amends and restates the terms of the Subsidiary Guaranty dated May 20, 2004,
delivered at the time the Loan was made.

                                   AGREEMENTS

     NOW, THEREFORE, Subsidiary Guarantors, in consideration of the matters
described in the foregoing Recitals, which Recitals are incorporated herein and
made a part hereof, and for other good and valuable consideration, hereby agree
as follows:

     1. Subsidiary Guarantors absolutely, unconditionally, and irrevocably
guaranty to each of the Lenders:

                                       F-1

<PAGE>

          (a) the full and prompt payment of the principal of and interest on
     the Notes when due, whether at stated maturity, upon acceleration or
     otherwise, and at all times thereafter, and the prompt payment of all sums
     which may now be or may hereafter become due and owing under the Notes, the
     Loan Agreement, and the other Loan Documents;

          (b) the payment of all Enforcement Costs (as hereinafter defined in
     Paragraph 7 hereof); and

          (c) the full, complete, and punctual observance, performance, and
     satisfaction of all of the obligations, duties, covenants, and agreements
     of Borrower under the Loan Agreement and the Loan Documents.

All amounts due, debts, liabilities, and payment obligations described in
subparagraphs (a) and (b) of this Paragraph 1 are referred to herein as the
"Facility Indebtedness." All obligations described in subparagraph (c) of this
Paragraph 1 are referred to herein as the "Obligations." Subsidiary Guarantors
and Lenders agree that Subsidiary Guarantors' obligations hereunder shall not
exceed the greater of: (i) the aggregate amount of all monies received, directly
or indirectly, by Subsidiary Guarantors from Borrower after the date hereof
(whether by loan, capital infusion or other means), or (ii) the maximum amount
of the Facility Indebtedness not subject to avoidance under Title 11 of the
United States Code, as same may be amended from time to time, or any applicable
state law (the "Bankruptcy Code"). To that end, to the extent such obligations
would otherwise be subject to avoidance under the Bankruptcy Code if Subsidiary
Guarantors are not deemed to have received valuable consideration, fair value or
reasonably equivalent value for its obligations hereunder, each Subsidiary
Guarantor's obligations hereunder shall be reduced to that amount which, after
giving effect thereto, would not render such Subsidiary Guarantor insolvent, or
leave such Subsidiary Guarantor with an unreasonably small capital to conduct
its business, or cause such Subsidiary Guarantor to have incurred debts (or
intended to have incurred debts) beyond its ability to pay such debts as they
mature, as such terms are determined, and at the time such obligations are
deemed to have been incurred, under the Bankruptcy Code. In the event a
Subsidiary Guarantor shall make any payment or payments under this Guaranty each
other guarantor of the Facility Indebtedness shall contribute to such Subsidiary
Guarantor an amount equal to such non-paying Subsidiary Guarantor's pro rata
share (based on their respective maximum liabilities hereunder and under such
other guaranty) of such payment or payments made by such Subsidiary Guarantor,
provided that such contribution right shall be subordinate and junior in right
of payment in full of all the Facility Indebtedness to Lenders.

     2. In the event of any default by Borrower in making payment of the
Facility Indebtedness, or in performance of the Obligations, as aforesaid, in
each case beyond the expiration of any applicable grace period, Subsidiary
Guarantors agree, on demand by the Administrative Agent or the holder of a Note,
to pay all the Facility Indebtedness and to perform all the Obligations as are
then or thereafter become due and owing or are to be performed under the terms
of the Notes, the Loan Agreement, and the other Loan Documents.

     3. Subsidiary Guarantors do hereby waive (i) notice of acceptance of this
Guaranty by the Administrative Agent and the Lenders and any and all notices and
demands of every kind

                                       F-2

<PAGE>

which may be required to be given by any statute, rule or law, (ii) any defense,
right of set-off or other claim which Subsidiary Guarantors may have against
Borrower or which Subsidiary Guarantors or Borrower may have against the
Administrative Agent or the Lenders or the holder of a Note, (iii) presentment
for payment, demand for payment (other than as provided for in Paragraph 2
above), notice of nonpayment (other than as provided for in Paragraph 2 above)
or dishonor, protest and notice of protest, diligence in collection and any and
all formalities which otherwise might be legally required to charge Subsidiary
Guarantors with liability, (iv) any failure by the Administrative Agent and the
Lenders to inform Subsidiary Guarantors of any facts the Administrative Agent
and the Lenders may now or hereafter know about Borrower, the Facility, or the
transactions contemplated by the Loan Agreement, it being understood and agreed
that the Administrative Agent and the Lenders have no duty so to inform and that
Subsidiary Guarantors are fully responsible for being and remaining informed by
Borrower of all circumstances bearing on the existence or creation, or the risk
of nonpayment of the Facility Indebtedness or the risk of nonperformance of the
Obligations, and (v) any and all right to cause a marshalling of assets of
Borrower or any other action by any court or governmental body with respect
thereto, or to cause the Administrative Agent and the Lenders to proceed against
any other security given to a Lender in connection with the Facility
Indebtedness or the Obligations. Credit may be granted or continued from time to
time by the Lenders to Borrower without notice to or authorization from
Subsidiary Guarantors, regardless of the financial or other condition of
Borrower at the time of any such grant or continuation. The Administrative Agent
and the Lenders shall have no obligation to disclose or discuss with Subsidiary
Guarantors the Lenders' assessment of the financial condition of Borrower.
Subsidiary Guarantors acknowledge that no representations of any kind whatsoever
have been made by the Administrative Agent and the Lenders to Subsidiary
Guarantors. No modification or waiver of any of the provisions of this Guaranty
shall be binding upon the Administrative Agent and the Lenders except as
expressly set forth in a writing duly signed and delivered on behalf of the
Administrative Agent and the Lenders. Subsidiary Guarantors further agree that
any exculpatory language contained in the Loan Agreement, the Notes, and the
other Loan Documents shall in no event apply to this Guaranty, and will not
prevent the Administrative Agent and the Lenders from proceeding against
Subsidiary Guarantors to enforce this Guaranty.

     4. Subsidiary Guarantors further agree that Subsidiary Guarantors'
liability as guarantor shall in no way be impaired by any renewals or extensions
which may be made from time to time, with or without the knowledge or consent of
Subsidiary Guarantors of the time for payment of interest or principal under a
Note or by any forbearance or delay in collecting interest or principal under a
Note, or by any waiver by the Administrative Agent and the Lenders under the
Loan Agreement, or any other Loan Documents, or by the Administrative Agent or
the Lenders' failure or election not to pursue any other remedies they may have
against Borrower, or by any change or modification in a Note, the Loan
Agreement, or any other Loan Documents, or by the acceptance by the
Administrative Agent or the Lenders of any security or any increase,
substitution or change therein, or by the release by the Administrative Agent
and the Lenders of any security or any withdrawal thereof or decrease therein,
or by the application of payments received from any source to the payment of any
obligation other than the Facility Indebtedness, even though a Lender might
lawfully have elected to apply such payments to any part or all of the Facility
Indebtedness, it being the intent hereof that Subsidiary Guarantors shall remain
liable as principal for payment of the Facility Indebtedness and performance of
the Obligations until all

                                       F-3

<PAGE>

indebtedness has been paid in full and the other terms, covenants and conditions
of the Loan Agreement, and other Loan Documents and this Guaranty have been
performed, notwithstanding any act or thing which might otherwise operate as a
legal or equitable discharge of a surety. Subsidiary Guarantors further
understand and agree that the Administrative Agent and the Lenders may at any
time enter into agreements with Borrower to amend and modify a Note, the Loan
Agreement or any of the other Loan Documents, or any thereof, and may waive or
release any provision or provisions of a Note, the Loan Agreement, or any other
Loan Document and, with reference to such instruments, may make and enter into
any such agreement or agreements as the Administrative Agent, the Lenders and
Borrower may deem proper and desirable, without in any manner impairing this
Guaranty or any of the Administrative Agent and the Lenders' rights hereunder or
any of Subsidiary Guarantors' obligations hereunder.

     5. This is an absolute, unconditional, complete, present and continuing
guaranty of payment and performance and not of collection. Subsidiary Guarantors
agree that its obligations hereunder shall be joint and several with any and all
other guarantees given in connection with the Facility from time to time.
Subsidiary Guarantors agree that this Guaranty may be enforced by the
Administrative Agent and the Lenders without the necessity at any time of
resorting to or exhausting any security or collateral, if any, given in
connection herewith or with a Note, the Loan Agreement, or any of the other Loan
Documents or by or resorting to any other guaranties, and Subsidiary Guarantors
hereby waive the right to require the Administrative Agent and the Lenders to
join Borrower in any action brought hereunder or to commence any action against
or obtain any judgment against Borrower or to pursue any other remedy or enforce
any other right. Subsidiary Guarantors further agree that nothing contained
herein or otherwise shall prevent the Administrative Agent and the Lenders from
pursuing concurrently or successively all rights and remedies available to them
at law and/or in equity or under a Note, the Loan Agreement or any other Loan
Documents, and the exercise of any of their rights or the completion of any of
their remedies shall not constitute a discharge of any of Subsidiary Guarantors'
obligations hereunder, it being the purpose and intent of Subsidiary Guarantors
that the obligations of such Subsidiary Guarantors hereunder shall be primary,
absolute, independent and unconditional under any and all circumstances
whatsoever. Neither Subsidiary Guarantors' obligations under this Guaranty nor
any remedy for the enforcement thereof shall be impaired, modified, changed or
released in any manner whatsoever by any impairment, modification, change,
release or limitation of the liability of Borrower under a Note, the Loan
Agreement or any other Loan Document or by reason of Borrower's bankruptcy or by
reason of any creditor or bankruptcy proceeding instituted by or against
Borrower. This Guaranty shall continue to be effective and be deemed to have
continued in existence or be reinstated (as the case may be) if at any time
payment of all or any part of any sum payable pursuant to a Note, the Loan
Agreement or any other Loan Document is rescinded or otherwise required to be
returned by the payee upon the insolvency, bankruptcy, or reorganization of the
payor, all as though such payment to such Lender had not been made, regardless
of whether such Lender contested the order requiring the return of such payment.
The obligations of Subsidiary Guarantors pursuant to the preceding sentence
shall survive any termination, cancellation, or release of this Guaranty.

     6. This Guaranty shall be assignable by a Lender to any assignee of all or
a portion of such Lender's rights under the Loan Documents.

                                       F-4

<PAGE>

     7. If: (i) this Guaranty, a Note, or any of the Loan Documents are placed
in the hands of an attorney for collection or is collected through any legal
proceeding; (ii) an attorney is retained to represent the Administrative Agent
or any Lender in any bankruptcy, reorganization, receivership, or other
proceedings affecting creditors' rights and involving a claim under this
Guaranty, a Note, the Loan Agreement, or any Loan Document; (iii) an attorney is
retained to enforce any of the other Loan Documents or to provide advice or
other representation with respect to the Loan Documents in connection with an
enforcement action or potential enforcement action; or (iv) an attorney is
retained to represent the Administrative Agent or any Lender in any other legal
proceedings whatsoever in connection with this Guaranty, a Note, the Loan
Agreement, any of the Loan Documents, or any property subject thereto (other
than any action or proceeding brought by any Lender or participant against the
Administrative Agent alleging a breach by the Administrative Agent of its duties
under the Loan Documents), then Subsidiary Guarantors shall pay to the
Administrative Agent or such Lender upon demand all reasonable attorney's fees,
costs and expenses, including, without limitation, court costs, filing fees and
all other costs and expenses incurred in connection therewith (all of which are
referred to herein as "Enforcement Costs"), in addition to all other amounts due
hereunder.

     8. The parties hereto intend that each provision in this Guaranty comports
with all applicable local, state and federal laws and judicial decisions.
However, if any provision or provisions, or if any portion of any provision or
provisions, in this Guaranty is found by a court of law to be in violation of
any applicable local, state or federal ordinance, statute, law, administrative
or judicial decision, or public policy, and if such court should declare such
portion, provision or provisions of this Guaranty to be illegal, invalid,
unlawful, void or unenforceable as written, then it is the intent of all parties
hereto that such portion, provision or provisions shall be given force to the
fullest possible extent that they are legal, valid and enforceable, that the
remainder of this Guaranty shall be construed as if such illegal, invalid,
unlawful, void or unenforceable portion, provision or provisions were not
contained therein, and that the rights, obligations and interest of the
Administrative Agent and the Lender or the holder of a Note under the remainder
of this Guaranty shall continue in full force and effect.

     9. Any indebtedness of Borrower to Subsidiary Guarantors now or hereafter
existing is hereby subordinated to the Facility Indebtedness. Subsidiary
Guarantors will not seek, accept, or retain for Subsidiary Guarantors' own
account, any payment from Borrower on account of such subordinated debt at any
time when a Default or Event of Default exists under the Loan Agreement or the
Loan Documents, and any such payments to Subsidiary Guarantors made while any
Default or Event of Default then exists under the Loan Agreement or the Loan
Documents on account of such subordinated debt shall be collected and received
by Subsidiary Guarantors in trust for the Lenders and shall be paid over to the
Administrative Agent on behalf of the Lenders on account of the Facility
Indebtedness without impairing or releasing the obligations of Subsidiary
Guarantors hereunder.

     10. Subsidiary Guarantors hereby subordinate to the Facility Indebtedness
any and all claims and rights, including, without limitation, subrogation
rights, contribution rights, reimbursement rights and set-off rights, which
Subsidiary Guarantors may have against Borrower arising from a payment made by
Subsidiary Guarantors under this Guaranty and agree

                                       F-5

<PAGE>

that, until the entire Facility Indebtedness is paid in full, not to assert or
take advantage of any subrogation rights of Subsidiary Guarantors or the Lenders
or any right of Subsidiary Guarantors or the Lenders to proceed against (i)
Borrower for reimbursement, or (ii) any other guarantor or any collateral
security or guaranty or right of offset held by the Lenders for the payment of
the Facility Indebtedness and performance of the Obligations, nor shall
Subsidiary Guarantors seek or be entitled to seek any contribution or
reimbursement from Borrower or any other guarantor in respect of payments made
by Subsidiary Guarantors hereunder. It is expressly understood that the
agreements of Subsidiary Guarantors set forth above constitute additional and
cumulative benefits given to the Lenders for their security and as an inducement
for their extension of credit to Borrower.

     11. Any amounts received by a Lender from any source on account of any
indebtedness may be applied by such Lender toward the payment of such
indebtedness, and in such order of application, as a Lender may from time to
time elect.

     12. Subsidiary Guarantors hereby submit to personal jurisdiction in the
State of Illinois for the enforcement of this Guaranty and waives any and all
personal rights to object to such jurisdiction for the purposes of litigation to
enforce this Guaranty. Subsidiary Guarantors hereby consent to the jurisdiction
of either the Circuit Court of Cook County, Illinois, or the United States
District Court for the Northern District of Illinois, in any action, suit, or
proceeding which the Administrative Agent or a Lender may at any time wish to
file in connection with this Guaranty or any related matter. Subsidiary
Guarantors hereby agree that an action, suit, or proceeding to enforce this
Guaranty may be brought in any state or federal court in the State of Illinois
and hereby waives any objection which Subsidiary Guarantors may have to the
laying of the venue of any such action, suit, or proceeding in any such court;
provided, however, that the provisions of this Paragraph shall not be deemed to
preclude the Administrative Agent or a Lender from filing any such action, suit,
or proceeding in any other appropriate forum.

     13. All notices and other communications provided to any party hereto under
this Agreement or any other Loan Document shall be in writing or by telex or by
facsimile and addressed or delivered to such party at its address set forth
below or at such other address as may be designated by such party in a notice to
the other parties. Any notice, if mailed and properly addressed with postage
prepaid, shall be deemed given when received; any notice, if transmitted by
facsimile, shall be deemed given when transmitted. Notice may be given as
follows:

          To Subsidiary Guarantors:

               c/o Developers Diversified Realty Corporation
               3300 Enterprise Parkway
               Beachwood, Ohio 44122

               Attention: Chief Financial Officer

               Telephone: (216) 755-5775
               Facsimile: (216) 755-1775

                                       F-6

<PAGE>

          With a copy to:

               3300 Enterprise Parkway
               Beachwood, Ohio 44122

               Telephone: (216) 755-5650
               Facsimile: (216) 755-1560
               Attention: General Counsel

          To JPMorgan Chase as Administrative Agent and as a Lender:

               JPMorgan Chase Bank, N.A.
               277 Park Avenue
               Third Floor
               New York, NY 10172

               Telephone: (212) 622-8177
               Facsimile: (646) 534-0574
               Attention: Kimberly Turner

          With a copy to:

               Sonnenschein Nath & Rosenthal LLP
               8000 Sears Tower
               Chicago, Illinois 60606
               Attention: Steven R. Davidson, Esq.

               Telephone: (312) 876-8238
               Facsimile: (312) 876-7934

          If to any other Lender, to its address set forth in the Loan
          Agreement.

     14. This Guaranty shall be binding upon the heirs, executors, legal and
personal representatives, successors and assigns of Subsidiary Guarantors and
shall inure to the benefit of the Administrative Agent and the Lenders'
successors and assigns.

     15. This Guaranty shall be construed and enforced under the internal laws
of the State of Illinois.

     16. SUBSIDIARY GUARANTORS, THE ADMINISTRATIVE AGENT AND THE LENDERS, BY
THEIR ACCEPTANCE HEREOF, EACH HEREBY WAIVE ANY RIGHT TO A TRIAL BY JURY IN ANY
ACTION OR PROCEEDING TO ENFORCE OR DEFEND ANY RIGHT UNDER THIS GUARANTY OR ANY
OTHER LOAN DOCUMENT OR RELATING THERETO OR ARISING FROM THE LENDING RELATIONSHIP
WHICH IS THE SUBJECT OF THIS GUARANTY AND AGREE THAT ANY SUCH ACTION OR
PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY.

                                       F-7

<PAGE>

     17. From time to time, additional Subsidiaries may be deemed to be parties
to this Guaranty automatically pursuant to Section 6.13 of the Loan Agreement
and from time to time, certain of such parties may execute a joinder
substantially in the form of Exhibit A hereto. Each such Subsidiary shall be a
Subsidiary Guarantor, and be bound by all of the terms and provisions of this
Guaranty, subject to the terms of Section 18.

     18. Notwithstanding anything to the contrary contained herein, at such time
as a Subsidiary Guarantor enters into a transaction which prohibits it from
being a Subsidiary Guarantor hereunder it shall be deemed to be automatically
released as a Subsidiary Guarantor provided no Default then exists until such
time, if any, as it again is required to be a Subsidiary Guarantor pursuant to
Section 6.13 of the Loan Agreement. Upon written request from such Subsidiary
Guarantor to confirm such release, and delivery to Administrative Agent of such
documentation supporting the request as Administrative Agent may request,
Administrative Agent will deliver to such Subsidiary Guarantor written evidence
of its release as a Subsidiary Guarantor.

     19. Notwithstanding anything to the contrary contained herein, if a
Subsidiary Guarantor which owns more than one Project, either directly or
indirectly through the ownership of Capital Stock in another Subsidiary of
Borrower (a "Multi-Property Guarantor"), owns an interest in any Capital Stock
in a Subsidiary of Borrower that is excluded from being a Subsidiary Guarantor
pursuant to Section 6.13 of the Loan Agreement (an "Excluded Entity"), then the
amounts recoverable by the Lenders from such Multi-Property Guarantor under this
Guaranty shall exclude any and all amounts arising from such Multi-Property
Guarantor's right, title and interest in the Capital Stock of such Excluded
Entity (including, without limitation, any right of such Multi-Property
Guarantor to receive distributions or other payments on account of any Capital
Stock of such Excluded Entity) or from the assets of such Excluded Entity
(whether pursuant to a judgment lien or otherwise).

                                       F-8

<PAGE>

     IN WITNESS WHEREOF, Subsidiary Guarantors have delivered this Guaranty in
the State of Illinois as of the date first written above.

March 10, 2006

EIN #06-1643946
CENTERTON SQUARE LLC
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1791911
DEVELOPERS DIVERSIFIED OF
ALABAMA, INC.
an Alabama corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #31-1566727
DEVELOPERS DIVERSIFIED CENTENNIAL
PROMENADE LP, an Ohio limited partnership
By GS DDR LLC
Its General Partner
    By DDR Realty Company
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #31-1553251
DEVELOPERS DIVERSIFIED COOK'S
CORNER LP, an Ohio limited partnership
By DDR DownREIT LLC
Its General Partner
    By Developers Diversified Realty
       Corporation, its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1887661
DEVELOPERS DIVERSIFIED OF
INDIANA, INC., an Ohio corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1852888
DEVELOPERS DIVERSIFIED OF
MISSISSIPPI, INC.
an Ohio corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1841352
DEVELOPERS DIVERSIFIED OF PENNSYLVANIA, INC.
an Ohio corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1907043
DEVELOPERS DIVERSIFIED OF TENNESSEE, INC.
an Ohio corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1913613
DD DEVELOPMENT COMPANY II, INC.
an Ohio corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #62-1834187
DDR ASPEN GROVE LIFESTYLE CENTER PROPERTIES LLC
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

                                       F-9

<PAGE>
March 10, 2006

EIN #06-1653814
DDR CHANDLER LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1858298
DDR CONTINENTAL LP
an Ohio limited partnership
By DDR DownREIT LLC
Its General Partner
    By Developers Diversified Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1834081
DDR COPPER COUNTRY LLC
a Delaware limited liability company
By DDR Michigan II LLC
Its Sole Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #06-1653812
DDR CROSSROADS CENTER LLC
an Ohio limited liability company
By Developers Diversified of Mississippi, Inc.
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1870042
DDR DB OPPORTUNITY SUB INC.
an Ohio corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #74-2937278
DDR DB SA VENTURES LP
a Texas limited partnership
By Bandera Pointe Investment LLC
Its General Partner
   By Retail Value Investment Program IIIC
      Limited Partnership
   Its Sole Member
     By Developers Diversified Realty Corporation
     Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1853588
DDR DEER PARK TOWN CENTER LLC,
an Ohio limited liability company
By Retail Value Investment Program Limited
   Partnership IIIB
Its Managing Member
  By Coventry Real Estate Partners, Ltd.
     d/b/a Coventry Real Estate Partners, LLC
  Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1901821
DDR DOWNREIT LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #01-0730280
DDR EASTGATE PLAZA LLC
a Delaware limited liability company
By DDR Woodmont LLC
Its Sole Member
    By Developers Diversified Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #01-0730291
DDR FC LAKEPOINTE LLC
a Delaware limited liability company
By DDR Woodmont LLC
Its Sole Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1990576
DDR FC LAKEPOINTE I LP
a Texas limited partnership
By DDR Fossil Creek LLC
Its General Partner
   By DDR Woodmont LLC
   Its Sole Member
    By Developers Diversified Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1868221
DDR FAMILY CENTERS LP
a Delaware limited partnership
By DDR DownREIT LLC
Its General Partner
    By Developers Diversified Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0508937
DDR FLATIRON LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #82-0552195
DDR FOSSIL CREEK LLC
a Delaware limited liability company
By DDR Woodmont LLC
Its Sole Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #82-0552188
DDR HARBISON COURT LLC
a Delaware limited liability company
By DDR Woodmont LLC
Its Sole Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E, Weiss, Vice President

EIN #58-2103271
DDR HENDON NASSAU PARK II LP
a Georgia limited partnership
By DDR Nassau Park II Inc.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #37-1419056
DDR INDEPENDENCE LLC
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #30-0244784
DDR JUPITER FALLS LLC
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #36-4386729
DDR KILDEER INC.
an Illinois corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #33-0878094
DDR LONG BEACH LLC
a Delaware limited liability company
By DDR Urban LP
Its Sole Member
   By DDR Urban, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #45-0474925
DDR MANAGEMENT LLC
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #
DDR MDT HOLDINGS I TRUST
a Maryland real estate investment trust

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #
DDR MDT HOLDINGS II TRUST
a Maryland real estate investment trust

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #
DDR MDT HOLDINGS III TRUST
a Maryland real estate investment trust

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2199953
DDR MERRIAM VILLAGE LLC
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #31-0112201
DDR MIAMI AVENUE LLC
an Delaware limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1880868
DDR MICHIGAN II LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2229478
DDR NASSAU PAVILION ASSOCIATES LP
a Georgia limited partnership
By DDR Nassau Pavilion Inc.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #33-0835467
DDR OCEANSIDE LLC
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #52-2121685
DDR OFFICE FLEX CORPORATION
a Delaware corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1902261
DDR OHIO OPPORTUNITY LLC
an Ohio limited liability company
By DDR DownREIT LLC
Its Managing Member
    By Developers Diversified Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1924926
DDR OHIO OPPORTUNITY II LLC
an Ohio limited liability company
By DDR DownREIT LLC
Its Managing Member
    By Developers Diversified Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1924927
DDR OHIO OPPORTUNITY III LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #06-1653811
DDR PARADISE LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #02-0651789
DDR PASEO LLC
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1932167
DDR QUEENSWAY LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #52-2109420
DDR REALTY COMPANY
a Maryland Real Estate Investment Trust

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #33-0846331
DDR RENO LLC
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2342891
DDR RIVERCHASE II LLC
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #
DDR SANSONE DEVELOPMENT VENTURES LLC,
a Missouri limited liability company
By DD Development Company II, Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #01-0643139
DDR SM LLC
a Delaware limited liability company
By DD Development Company II, Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #30-0021143
DDR TINTON FALLS LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1861748
DDR URBAN LP
a Delaware limited partnership
By DDR Urban, Inc.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #91-1997671
DDR UNIVERSITY SQUARE ASSOCIATES L.C.,
a Utah limited liability company
By DDR Family Centers LP
Its Managing Member
   By DDR DownREIT LLC
   Its General Partner
      By Developers Diversified Realty Corporation
      Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #33-0823709
DDR/VAN NESS OPERATING COMPANY, L.P.
a Delaware limited partnership
By DDR Van Ness, Inc.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #30-0044273
DDR VAN NESS, INC.
an Ohio corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #91-1997685
DDR VIC I L.C.
a Utah limited liability company
By DDR Family Centers LP
Its Managing Member
    By DDR DownREIT LLC
    Its General Partner
        By Developers Diversified Realty Corporation
        Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #61-1403755
DDR WATERTOWN LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1909252
DDR WILSHIRE, INC.
an Ohio corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #33-1012011
DDR WOODMONT LLC
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #61-1448452
DDR XENIA AND NEW BERN LLC
a Delaware limited liability company
By DDR Continental LP
Its Sole Member
   By DDR DownREIT LLC
   Its General Partner
    By Developers Diversified Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #13-3923870
DDRA COMMUNITY CENTERS FOUR, L.P.
a Texas limited partnership
By Pedro Community Centers, Inc.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #52-2119472
DDRA COMMUNITY CENTERS FIVE, L.P.
a Delaware limited partnership
By DD Community Centers Five, Inc.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #52-2156229
DDRA COMMUNITY CENTERS SIX, L.P.
a Delaware limited partnership
By DDR Realty Company
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #52-2196613
DDRA COMMUNITY CENTERS SEVEN, L.P.
a Delaware limited partnership
By DD Community Centers Seven, Inc.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #52-2212509
DDRA COMMUNITY CENTERS EIGHT, L.P.
a Delaware limited partnership
By DD Community Centers Eight, Inc.
A General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1863882
DDRC GATEWAY LLC
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #31-1500729
DDRC GREAT NORTHERN LIMITED
PARTNERSHIP, an Ohio limited partnership
By DDR DownREIT LLC
Its General Partner
    By Developers Diversified Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1853584
DDRC MICHIGAN LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #34-1922640
DDRC PDK EASTON LLC
an Ohio limited liability company
By DD Development Company II, Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #31-1570068
DDRC PDK SALISBURY LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN# 34-1929157
DDRC PDK SALISBURY PHASE III LLC
an Ohio limited liability company
By DDRC PDK Salisbury LLC
Its Managing Member
    By Developers Diversified Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #11-3645066
DDRC PIKE ENTERTAINMENT LLC
a California limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN # 34-1859297
DDRC SALEM LLC
a Delaware limited liability company
By Retail Value Investment Program Limited
    Partnership IIA
Its Managing Member
    By Coventry Real Estate Partners, Ltd.
    Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1840198
DOTRS LIMITED LIABILITY COMPANY
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #31-1521543
EASTON MARKET LIMITED LIABILITY COMPANY,
a Delaware limited liability company
By DDR Continental LP
Its Managing Member
  By DDR DownREIT LLC
  Its General Partner
    By Developers Diversified Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN#30-0013458
ENERGY MANAGEMENT
STRATEGIES, INC.
a Delaware corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #87-0521236
FORT UNION ASSOCIATES LLC
a Utah limited liability company
By DDR Family Centers LP
Its Member Manager
  By DDR DownREIT LLC
  Its General Partner
    By Developers Diversified Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1953726
GS BOARDMAN LLC
a Delaware limited liability company
By GS DDR LLC
Its Managing Member
    By  DDR Realty Company
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1953724
GS BRENTWOOD LLC
a Delaware limited liability company
By GS DDR LLC
Its Managing Member
    By  DDR Realty Company
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1953730
GS CENTENNIAL LLC
a Delaware limited liability company
By Developers Diversified Centennial
   Promenade LP
Its Managing Member
  By GS DDR LLC
  Its General Partner
   By DDR Realty Company
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #31-1767597
GS DDR LLC
an Ohio limited liability company
By  DDR Realty Company
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1953731
GS ERIE LLC
a Delaware limited liability company
By GS DDR LLC
Its Managing Member
   By  DDR Realty Company
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1953728
GS SUNSET LLC
a Delaware limited liability company
By GS DDR LLC
Its Managing Member
   By  DDR Realty Company
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #65-1175724
GS II BIG OAKS LLC
a Delaware limited liability company
By Developers Diversified of Mississippi, Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #65-1175700
GS II BROOK HIGHLAND LLC
a Delaware limited liability company
By Developers Diversified of Alabama, Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #02-0677488
GS II DDR LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #65-1175703
GS II GREEN RIDGE LLC
a Delaware limited liability company
By GS II DDR LLC
Its Managing Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #65-1175706
GS II INDIAN HILLS LLC
a Delaware limited liability company
By GS II DDR LLC
Its Managing Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #65-1175707
GS II JACKSONVILLE REGIONAL LLC
a Delaware limited liability company
By GS II DDR LLC
Its Managing Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #141875600
GS II MERIDIAN CROSSROADS LLC
a Delaware limited liability company
By GS II DDR LLC
Its Managing Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #65-1175714
GS II NORTH POINTE LLC
a Delaware limited liability company
By GS II DDR LLC
Its Managing Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #65-1175709
GS II OXFORD COMMONS LLC
a Delaware limited liability company
By GS II DDR LLC
Its Managing Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #65-1175717
GS II UNIVERSITY CENTRE LLC
a Delaware limited liability company
By GS II DDR LLC
Its Managing Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #65-1175721
GS II UPTOWN SOLON LLC
a Delaware limited liability company
By GS II DDR LLC
Its Managing Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1902994
HAGERSTOWN DEVELOPMENT LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1910431
HAGERSTOWN TIF LLC
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1856797
HENDON/DDR/BP, LLC
a Delaware limited liability company
By Retail Value Investment Program Limited
   Partnership I
Its Managing Member
    By Coventry Real Estate Partners, Ltd.
    Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #87-6132830
HERMES ASSOCIATES
a Utah general partnership
By DDR Family Centers LP
Its General Partner
   By DDR DownREIT LLC
   Its General Partner
     By Developers Diversified Realty Corporation
     Its Managing Member

<PAGE>

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #87-6132830
HERMES ASSOCIATES, LTD.
a Utah limited partnership
By DDR Family Centers LP
Its General Partner
   By DDR DownREIT LLC
   Its General Partner
      By Developers Diversified Realty Corporation
      Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1835230
HIGHLAND GROVE LIMITED
LIABILITY COMPANY
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #43-1857731
JEFFERSON COUNTY PLAZA LLC
a Missouri limited liability company
By DDR Sansone Development Ventures LLC
Its Managing Member
   By DD Development Company, Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #52-2203054
LIBERTY FAIR VA LP
a Virginia limited partnership
By DDR Liberty Fair, Inc.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1738278
LIBERTY FAIR VA II LP
a Virginia limited partnership
By Developers Diversified Realty Corporation
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0061583
MT. NEBO POINTE LLC
an Ohio limited liability company
By Developers Diversified of Pennsylvania, Inc.
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1646725
PASEO COLORADO HOLDINGS LLC
a Delaware limited liability company
By DDR Paseo LLC
Its Administrative Managing Member
    By Developers Diversified Realty Corporation
    Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1884640
PLAINVILLE CONNECTICUT L.L.C.
an Ohio limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1560895
PLAINVILLE DEVELOPMENT, L.P.
an Ohio limited partnership
By Retail Value Investment Program Limited Partnership IA
Its General Partner
    By Developers Diversified Realty Corporation
    Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #03-0394720
PLAINVILLE INVESTMENT IA, LLC
a Delaware limited liability company
By Retail Value Investment Program Limited
   Partnership IA
Its Sole Member
   By Developers Diversified Realty Corporation
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #87-0521235
RIVERDALE RETAIL ASSOCIATES, L.C.
a Utah limited liability company
By DDR Family Centers LP
Its Member Manager
  By DDR DownREIT LLC
  Its General Partner
    By Developers Diversified Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #87-0555190
ROCKY MOUNTAIN REAL ESTATE L.L.C.
a Utah limited liability company
By Riverdale Retail Associates, L.C.
Its Managing Member
   By DDR Family Centers LP
   Its Member Manager
    By DDR DownREIT LLC
    Its General Partner
       By Developers Diversified Realty Corporation
       Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #86-0778309
SHEA AND TATUM ASSOCIATES LIMITED PARTNERSHIP
an Arizona limited partnership
By DDR Paradise LLC
Its General Partner
   By Developers Diversified Realty Corporation
   Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #48-1274461
SHORESALES, LLC
a Delaware limited liability company

By: /s/ Daniel B. Hurwitz
    ---------------------------------
    Daniel B. Hurwitz, Chief Investment Officer

EIN #30-0176115
SOUTHTOWN REALTY LLC
a Delaware limited liability company
By DDR Realty Company
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #87-0572860
TFCM ASSOCIATES, LLC
a Utah limited liability company
By DDR Family Centers LP
Its Member Manager
  By DDR DownREIT LLC
  Its General Partner
     By Developers Diversified Realty Corporation
     Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #62-1600792
TOWN CENTER PLAZA, L.L.C.
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #87-0485325
UNIVERSITY SQUARE ASSOCIATES, LTD.
a Utah limited partnership
By DDR Family Centers LP
Its General Partner
   By DDR DownREIT LLC
   Its General Partner
     By Developers Diversified Realty Corporation
     Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #03-0394712
BANDERA POINTE INVESTMENT LLC
a Delaware limited liability company
By Retail Value Investment Program IIIC
   Limited Partnership
Its Sole Member
   By Developers Diversified Realty Corporation
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #34-1871282
COVENTRY REAL ESTATE PARTNERS, LTD.,
an Ohio limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1912304
COVENTRY ROUND ROCK LLC
an Ohio limited liability company
By Coventry Real Estate Partners, Ltd.
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1874420
RETAIL VALUE INVESTMENT PROGRAM
LIMITED PARTNERSHIP I
a Delaware limited partnership
By Coventry Real Estate Partners, Ltd.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1920347
RETAIL VALUE INVESTMENT PROGRAM
LIMITED PARTNERSHIP IA
a Delaware limited partnership
By Developers Diversified Realty Corporation
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #
RETAIL VALUE INVESTMENT PROGRAM
LIMITED PARTNERSHIP IIA
a Delaware limited partnership
By Coventry Real Estate Partners, Ltd.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #34-1939224
RETAIL VALUE INVESTMENT PROGRAM
IIIC LIMITED PARTNERSHIP
a Delaware limited partnership
By Developers Diversified Realty Corporation
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #42-1548210
TECH RIDGE COVENTRY LLC
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #75-2784050
AIP/GREENBRIER GP, INC.
a Texas corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #
AIP OFFICE FLEX II, LLC
an Ohio limited liability company
By American Industrial Properties REIT
Its Manager

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #75-2783840
AIP/POST OFFICE GP, INC.
a Delaware corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #84-1285970
AIP PROPERTIES #1, L.P.
a Delaware limited partnership
By AIP Tamarac, Inc.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #75-2676417
AIP PROPERTIES #3 GP, INC.
a Texas corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #75-2676418
AIP PROPERTIES #3, L.P.
a Delaware limited partnership
By AIP Properties #3 GP, Inc.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #75-2747375
AIP-SWAG GP, INC.
a Texas corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #75-2726857
AIP-SWAG OPERATING PARTNERSHIP, L.P.,
a Delaware limited partnership
By AIP-SWAG GP, Inc.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #84-1285966
AIP TAMARAC, INC.
a Texas corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #75-6335572
AMERICAN INDUSTRIAL PROPERTIES REIT,
a Texas real estate investment trust

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #75-2518113
AMERICAN INDUSTRIAL PROPERTIES REIT, INC.,
a Maryland corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #75-2775567
CHELMSFORD ASSOCIATES LLC
a Delaware limited liability company
By American Industrial Properties REIT
Its Manager

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #54-1905917
DDR/TECH 29 LIMITED PARTNERSHIP
a Maryland limited partnership
By DDR Office Flex Corporation
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #54-2029800
PARCEL J-1B LIMITED PARTNERSHIP
a Virginia limited partnership
By AIP/Post Office GP, Inc.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #52-1743838
TECH CENTER DEVELOPMENT ASSOCIATES LIMITED PARTNERSHIP
a Maryland limited partnership
By DDR Office Flex Corporation
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #54-1412012
TECH CENTER 29 LIMITED PARTNERSHIP
a Maryland limited partnership
By DDR Office Flex Corporation
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #54-1718657
TECH CENTER 29 PHASE II LIMITED PARTNERSHIP,
a Maryland limited partnership
By DDR Office Flex Corporation
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #
USAA INCOME PROPERTIES IV TRUST
a Trust organized and existing under a Declaration
of Trust dated September 30, 1987
By American Industrial Properties REIT
Its Trustee

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #
SERVICE BATON ROUGE, LLC
a Delaware limited liability company
By Service Parent, LLC
Its Sole Member
   By Developers Diversified Realty Corporation
   Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #
SERVICE MACON, LLC
a Delaware limited liability company
By Service Parent, LLC
Its Sole Member
   By Developers Diversified Realty Corporation
   Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1656512
SERVICE PARENT, LLC
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #
SERVICE PENSACOLA, LLC
a Delaware limited liability company
By Service Parent, LLC
Its Sole Member
   By Developer Diversified Realty Corporation
   Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #
SERVICE TUSCALOOSA, LLC
a Delaware limited liability company
By Service Parent, LLC
Its Sole Member
   By Developers Diversified Realty Corporation
   Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #20-1656782
SERVICE LONGVIEW GP, LLC
a Delaware limited liability company
By Service Parent, LLC
Its Sole Member
   By Developers Diversified Realty Corporation
   Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1656835
SERVICE LONGVIEW, L.P.
a Texas limited partnership
By Service Longview GP, LLC
Its General Partner
  By Service Parent, LLC
  Its Sole Member
    By Developers Diversified Realty Corporation
    Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1656881
SERVICE TYLER GP, LLC
a Delaware limited liability company
By Service Parent, LLC
Its Sole Member
   By Developers Diversified Realty Corporation
   Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1656927
SERVICE TYLER, L.P.
a Texas limited partnership
By Service Tyler GP, LLC
Its General Partner
  By Service Parent, LLC
  Its Sole Member
    By Developers Diversified Realty Corporation
    Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #84-1354587
BLACK CHERRY LIMITED LIABILITY COMPANY,
a Colorado limited liability company
By JDN Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #38-3427485
CANAL STREET PARTNERS, L.L.C.
a Michigan limited liability company
By JDN Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2223407
CHESTERFIELD EXCHANGE, LLC
a Georgia limited liability company
By JDN Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #61-1465703
DDR/1ST CAROLINA APEX PHASE III LLC
a Delaware limited liability company
By Developers Diversified Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2453432
FAYETTEVILLE BLACK INVESTMENT, INC.
a Georgia corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #58-2509312
FAYETTEVILLE EXCHANGE, LLC
a Georgia limited liability company
By JDN Realty Corporation
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #56-2284631
FLATACRES MARKETCENTER, LLC
a Georgia limited liability company
By JDN Intermountain Holdings, Inc.
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #84-1435218
FT. COLLINS PARTNERS I, LLC
a Colorado limited liability company
By JDN Intermountain Holdings, Inc.
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2488320
GEORGIA FINANCE CORPORATION
a Delaware corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2461061
HENDON/ATLANTIC RIM JOHNS CREEK, LLC
a Georgia limited liability company
By DDR DownREIT LLC
Its Managing Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

IN #58-2496005
HICKORY HOLLOW EXCHANGE, LLC
a Georgia limited liability company
By JDN Development Company, Inc.
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2148124
JDN DEVELOPMENT COMPANY, INC.
a Delaware corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2384898
JDN DEVELOPMENT INVESTMENT, L.P.
a Georgia limited partnership
By JDN Development Company, Inc.
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2385460
JDN DEVELOPMENT LP, INC.
a Delaware corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2463351
JDN INTERMOUNTAIN DEVELOPMENT CORP.
a Delaware corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2512033
JDN INTERMOUNTAIN DEVELOPMENT, PIONEER HILLS, LLC
a Georgia limited liability company
By JDN Intermountain Holdings, Inc.
Its Sole Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #58-2476049
JDN INTERMOUNTAIN DEVELOPMENT, PARKER PAVILION, LLC
a Georgia limited liability company
By JDN Real Estate - Parker Pavilions, L.P.
Its Sole Member
  By JDN Development Investment, L.P.
  Its General Partner
    By JDN Development Company, Inc.
    Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #84-1196006
JDN INTERMOUNTAIN HOLDINGS, INC.
a Colorado corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #62-1608255
JDN OF ALABAMA REALTY CORPORATION
an Alabama corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #02-0619063
JDN REAL ESTATE - APEX, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2490180
JDN REAL ESTATE - BRIDGEWOOD FORT WORTH, L.P.,
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2496037
JDN REAL ESTATE - CONYERS, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2488802
JDN REAL ESTATE - CUMMING, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2472037
JDN REAL ESTATE - ERIE, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2450207
JDN REAL ESTATE - FAYETTEVILLE, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #58-2598344
JDN REAL ESTATE - FREEHOLD, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2455618
JDN REAL ESTATE - FRISCO, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2436327
JDN REAL ESTATE - GULF BREEZE II, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2560461
JDN REAL ESTATE - HAMILTON, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2460243
JDN REAL ESTATE - HICKORY CREEK, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

<PAGE>

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2437713
JDN REAL ESTATE - LAKELAND, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2450205
JDN REAL ESTATE - MCDONOUGH, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2554494
JDN REAL ESTATE - MCDONOUGH II, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #58-2451903
JDN REAL ESTATE - MCKINNEY, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2578314
JDN REAL ESTATE - MESQUITE, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2609930
JDN REAL ESTATE - NORWOOD, LLC
a Georgia limited liability company
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #03-0474137
JDN REAL ESTATE - OAKLAND, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2554496
JDN REAL ESTATE - OVERLAND PARK, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

<PAGE>

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2475331
JDN REAL ESTATE - PARKER PAVILIONS, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2517672
JDN REAL ESTATE - PENSACOLA, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2658828
JDN REAL ESTATE - RALEIGH, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #58-2566079
JDN REAL ESTATE - SACRAMENTO, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2598344
JDN REAL ESTATE - STONE MOUNTAIN, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #56-2283470
JDN REAL ESTATE - SUWANEE, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2590532
JDN REAL ESTATE - TURNER HILL, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2496038
JDN REAL ESTATE - WEST LAFAYETTE, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

<PAGE>

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2475332
JDN REAL ESTATE - WEST LANSING, L.P.
a Georgia limited partnership
By JDN Development Investment, L.P.
Its General Partner
   By JDN Development Company, Inc.
   Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2392185
JDN REALTY AL, INC.
an Alabama corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-1468053
JDN REALTY CORPORATION
a Maryland corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2421961
JDN REALTY CORPORATION GP, INC.
a Delaware corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #58-2475329
JDN REALTY HOLDINGS, L.P.
a Georgia limited partnership
By JDN Realty Corporation
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2385210
JDN REALTY INVESTMENT, L.P.
a Georgia limited partnership
By JDN Realty Corporation
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2421960
JDN REALTY LP, INC.
a Delaware corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2380177
JDN WEST ALLIS ASSOCIATES LIMITED PARTNERSHIP,
a Georgia limited partnership
By JDN Realty Corporation
Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #
J&T OAKLAND, LLC
a Tennessee limited liability company
By JDN Real Estate - Oakland, L.P.
Its Managing Member
   By JDN Development Investment, L.P.
   Its General Partner
    By JDN Development Company, Inc.
    Its General Partner

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2484191
MITCHELL BRIDGE ASSOCIATES, INC.
a Georgia corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #43-1904582
ST. JOHN CROSSINGS, LLC
a Missouri limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #58-2197791
WHF, INC.
a Georgia corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1489815
93-1 CORTLAND ASSOCIATES, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #06-1608207
ASH-I ASSOCIATES, LLC
an Ohio limited liability company
By Ash Associates SPE, LLC
Its Managing Member
  By JDN Ash LLC
  Its Managing Member
    By JDN Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #16-1600738
ASH-L ASSOCIATES, LLC
an Ohio limited liability company
By Ash Associates SPE, LLC
Its Managing Member
  By JDN Ash LLC
  Its Managing Member
     By JDN Realty Corporation
     Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1489818
BENDERSON-ERIE ASSOCIATES, LLC
a New York limited liability company
By DDR GLH Erie Plaza Trust
Its Sole Member
   By Developers Diversified Realty Corporaton
   Its Sole Trustee

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1489819
BENDERSON-FRENCH ASSOCIATES, LLC
a New York limited liability company
By BG Transit JA II, LLC
Its Managing Member
  By DDR GLH LLC
  Its Managing Member
    By JDN QRS Inc.
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1510649
BENDERSON-MEDINA ASSOCIATES, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
  By JDN QRS Inc.
  Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1377125
BENDERSON-WAINBERG ASSOCIATES,  L.P.
a Delaware limited partnership
By DDR GLH GP Holdings LLC
Its General Partner
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1393095
BENDERSON-WAINBERG ASSOCIATES II, L.P.
a Delaware limited partnership
By DDR GLH GP Holdings LLC
Its General Partner
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1482437
BENDERSON-WARSAW ASSOCIATES, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1546434
BFW/PIKE ASSOCIATES, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #20-0947291
BG ALDEN STOP, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0953603
BG ARCADE STOP, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0972105
BG ARLINGTON ROAD, LLC
a Florida limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0954868
BG BCF, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0955006
BG BEAR ROAD, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0955156
BG BEAR ROAD II, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1064968
BG BIG FLATS I, LLC
a New York limited liability company
By BG Big Flats, LLC
Its Managing Member
  By DDR GLH LLC
  Its Managing Member
     By JDN QRS Inc.
     Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1064980
BG BIG FLATS II-III, LLC
a New York limited liability company
By BG Big Flats II-III SPE LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #20-1064993
BG BIG FLATS IV, LLC
a New York limited liability company
By BG Big Flats IV SPE LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0965839
BG BOULEVARD, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0974167
BG BOULEVARD II, LLC
a New York limited liability company
By BG Boulevard, LLC
Its Managing Member
  By DDR GLH LLC
  Its Managing Member
     By JDN QRS Inc.
     Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0960825
BG BOULEVARD III, LLC
a New York limited liability company
By BG Boulevard, LLC
Its Managing Member
  By DDR GLH LLC
  Its Managing Member
     By JDN QRS Inc.
     Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1793590
BG CANANDAIGUA LLC
a Delaware limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0973332
BG CHILI, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0960665
BG CULVER RIDGE, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0965963
BG D & L STOP, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #20-0966012
BG DANSVILLE STOP, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0966075
BG DEL-ARROW, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0966151
BG DEL-TON, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1260808
BG DELAWARE CONSUMER SQUARE LLC
a Delaware limited liability company
By BG Delaware Holdings LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1259965
BG DELAWARE HOLDINGS LLC
a Delaware limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0966240
BG DEWITT M & CEC, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0966545
BG EASTWOOD, LLC
a New York limited liability company
By DDR DownREIT LLC
Its Sole Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0996655
BG FAIRVIEW SQUARE, LLC
a Virginia limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0966950
BG GREECE, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #20-0966999
BG HAMBURG HD, LLC
a New York limited liability company
By JDN QRS Inc.

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0967050
BG HAMBURG SJB, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0967114
BG HAMBURG VILLGE, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0967194
BG HEN-JEF II, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0967294
BG HENRIETTA, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0977751
BG HIGHLANDS, LLC
a Florida limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0971655
BG HORIZON, LLC
a Florida limited liability company
By DDR DownREIT LLC
Its Sole Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0967363
BG KELLOGG STOP, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #20-0967495
BG LOCKPORT II, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0967637
BG MAPLE ROAD, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0967897
BG MCKINLEY, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0967731
BG MCKINLEY II, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1421985
BG MEADOWS SQUARE LLC
a Delaware limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0967948
BG MID CITY I, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0968023
BG MID CITY II, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0968079
BG MID CITY III, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0968301
BG MILESTRIP, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0968348
BG MILESTRIP II, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #20-0974783
BG M-K, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0968479
BG MOHAWK STOP, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0977692
BG MONMOUTH, LLC
a New Jersey limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0968655
BG NIAGARA HD, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0977885
BG NORTH CHARLESTON, LLC
a South Carolina limited liability company
By BG North Charleston SPE LLC
Its Managing Member
   By JDN Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0968823
BG ODP TONAWANDA, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0968874
BG OLEAN, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0968972
BG ONTARIO STOP, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #20-0977807
BG ORLAND PARK HD, LLC
a Illinois limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0972701
BG OUTER LOOP, LLC
a Kentucky limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0969004
BG PANORAMA, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0970619
BG PINE PLAZA, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0970624
BG PORTAGE STOP, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1316075
BG ROBINSON ROAD LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1443218
BG ROTONDA LLC
a Delaware limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0970659
BG SENECA RIDGE, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0970672
BG SHERIDAN-DELAWARE, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0970710
BG SHERIDAN-HARLEM II, LLC
a New York limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #20-0970792
BG SOUTHSIDE, LLC
a New York limited liability company
By BG Southside SPE LLC
Its Managing Member
   By JDN Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #06-1723726
BG THRUWAY, LLC
a Delaware limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0972957
BG TOLEDO, LLC
an Ohio limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0970893
BG TRANSIT JA II, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0972767
BG TURFWAY, LLC
a Kentucky limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0973184
BG UNION TOWN, LLC
a North Carolina limited liability company
By JDN BG Union Town LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1260993
BG UP LLC
a Delaware limited liability company
By BG M-K, LLC
Its Managing Member
  By DDR GLH LLC
  Its Managing Member
    By JDN QRS Inc.
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
       David E. Weiss, Vice President

EIN #20-1189875
BG VILLAGE LLC
a Delaware limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #20-0977634
BG WALKER, LLC
a Michigan limited liability company
By DDR DownREIT LLC
Its Sole Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0971446
BG WEST SENECA HD, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-0971489
BG WILLIAMSVILLE, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1100703
BG WNF LLC
a Delaware limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1584616
BUFFALO-BROAD ASSOCIATES, LLC
an Ohio limited liability company
By DDR DownREIT LLC
Its Sole Member
   By Developers Diversified Realty Corporation
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1613633
BUFFALO-DEWITT ASSOCIATES, LLC
a New York limited liability company
By JDN Realty Corporation
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1545054
BUFFALO-ELMWOOD ASSOCIATES, LLC
a New York limited liability company
By Buffalo-Elmwood SPE, LLC
Its Managing Member
  By DDR GLH LLC
  Its Managing Member
    By JDN QRS Inc.
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1564527
BUFFALO-ITHACA ASSOCIATES, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #16-1564527
BUFFALO-ITHACA ASSOCIATES I, LLC
a New York limited liability company
By Buffalo-Ithaca Associates, LLC
Its Managing Member
  By DDR GLH LLC
  Its Managing Member
    By JDN QRS Inc.
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #06-1723738
BUFFALO-LEROY HOLDINGS LLC
a Delaware limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #52-2382860
BUFFALO-MOORESVILLE, LLC
a New York limited liability company
By Buffalo-Post Falls Associates, L.L.C.
Its Managing Member
  By JDN Mooresville LLC
  Its Managing Member
    By JDN Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1590915
BUFFALO-NISKAYUNA ASSOCIATES, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #54-1549019
BUFFALO-NORFOLK ASSOCIATES, L.L.P.
a Virginia limited liability partnership
By DDR GLH Buffalo-Norfolk Holdings LLC
Its General Partner
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1599403
BUFFALO-SPRINGVILLE ASSOCIATES, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1549914
BUFFALO-SUNSET RIDGE ASSOCIATES, LLC
a New York limited liability company
By DDR GLH LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1605681
BUFFALO-WESTGATE ASSOCIATES, LLC
a New York limited liability company
By Buffalo-Westgate SPE, LLC
Its Managing Manager
  By JDN Westgate LLC
  Its Managing Member
    By JDN Realty Corporation
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>
March 10, 2006

EIN #06-1723741
DDR GLH FREEDOM PLAZA LLC
a Delaware limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1101682
DDR GLH HANOVER TRUST
a Delaware business trust
By Developers Diversified Realty Corporation
Its Sole Trustee

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1111274
DDR GLH MARKETPLACE PLAZA LLC
a Delaware limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1102757
DDR GLH LLC
a Delaware limited liability company
By JDN QRS Inc.
Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #16-1549913
HWWM ASSOCIATES, LLC
a New York limited liability company
By BG Thruway LLC
Its Managing Member
   By JDN QRS Inc.
   Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #61-1470368
JDN QRS INC.
a New York corporation

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #43-2004641
VICTOR SQUARE SPE, LLC
a New York limited liability company
By Victor Square SPE I LLC
Its Managing Member
    By JDN QRS Inc.
    Its Managing Member

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1999230
DDR ATLANTICO LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2000821
DDR CAMINO REAL LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1998129
DDR CARIBBEAN LLC
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1998282
DDR CARIBBEAN PROPERTY MANAGEMENT LLC
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #20-2000903
DDR CAYEY LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2000405
DDR CRP PORTFOLIO LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2000510
DDR CRP I PORTFOLIO LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2000619
DDR CRP II PORTFOLIO LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1999040
DDR CRV PORTFOLIO LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2000702
DDR DEL SOL LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2000993
DDR ESCORIAL LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1998749
DDR FAJARDO LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1998920
DDR GUAYAMA WM LLC, S.E.
a Delaware limited liability company

<PAGE>

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2090398
DDR HAMILTON LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2001086
DDR ISABELA LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1998440
DDR MPR PORTFOLIO LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

March 10, 2006

EIN #20-1998536
DDR NORTE LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1998650
DDR OESTE LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2001183
DDR PALMA REAL LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1998366
DDR PR VENTURES LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2051163
DDR PR VENTURES II LLC
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2000254
DDR REXVILLE LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-2000323
DDR RIO HONDO LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1999125
DDR SENORIAL LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

EIN #20-1998839
DDR VEGA BAJA LLC, S.E.
a Delaware limited liability company

By: /s/ David E. Weiss
    ---------------------------------
    David E. Weiss, Vice President

<PAGE>

                        EXHIBIT A TO SUBSIDIARY GUARANTY

                           FORM OF JOINDER TO GUARANTY

     THIS JOINDER is executed by __________, a __________ ("Subsidiary"), which
hereby agrees as follows:

     1. All capitalized terms used herein and not defined in this Joinder shall
have the meanings provided in that certain Subsidiary Guaranty (the "Guaranty")
dated as of __________, 200__ executed for the benefit of JPMorgan Chase Bank,
N.A., as Administrative Agent for itself and certain other lenders, with respect
to a loan from the Lenders to Developers Diversified Realty Corporation
("Borrower").

     2. As required by the Loan Agreement described in the Guaranty, Subsidiary
is executing this Joinder to become a party to the Guaranty.

     3. Each and every term, condition, representation, warranty, and other
provision of the Guaranty, by this reference, is incorporated herein as if set
forth herein in full and the undersigned agrees to fully and timely perform each
and every obligation of a Subsidiary Guarantor under such Guaranty.

                            [INSERT SIGNATURE BLOCK]

                                       S-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]